#LCSM Transcript
Healthcare social media transcript of the #LCSM hashtag.
– ().
See #LCSM Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | Brendon Stiles @BrendonStilesMD Hi #lcsm crew! I am excited for tonight’s chat. One of my favorite topics. Nothing moves the needle more for cancer patients than #Research! #lcsm |
| Brendon Stiles @BrendonStilesMD More info about tonight’s chat at https://t.co/Lx9qF406C9 #lcsm |
 | Jean Parks @geekbabe RT @BrendonStilesMD: Hi #lcsm crew! I am excited for tonight’s chat. One of my favorite topics. Nothing moves the needle more for cancer patients than #Research! #lcsm |
| Brendon Stiles @BrendonStilesMD If you are out there, please tweet #lcsm our way! |
 | Christine Qiong Wu @wi_qiong @BrendonStilesMD @lcsmchat Have the talk started? #lcsm |
 | #LCSM Chat @lcsmchat RT @BrendonStilesMD: Hi #lcsm crew! I am excited for tonight’s chat. One of my favorite topics. Nothing moves the needle more for cancer patients than #Research! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: More info about tonight’s chat at https://t.co/Lx9qF406C9 #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: If you are out there, please tweet #lcsm our way! |
| Brendon Stiles @BrendonStilesMD @wi_qiong @lcsmchat Just getting geared up. Please say hello to everyone! #lcsm |
| #LCSM Chat @lcsmchat @wi_qiong @BrendonStilesMD Starting right now. #lcsm |
 | Umberto Malapelle @UmbertoMalapel1 RT @StephenVLiu: #ELCC19 Entrectinib data in #NTRK #NSCLC presented by Luis Paz-Ares - RR 70%, median PFS 14.9 months, intracranial RR 67%! #LCSM #OncoAlert https://t.co/88t4xkKHEN |
 | Darrell Polk 1 @polksbc1 RT @livinglife82: Thanks @chrisdraft for an awesome experience to check out the @dallascowboys facilities. The attention to detail shows why they have been so successful. I owe you one 😘. #grateful #lungcancer #Dallas #TeamBriggs #LCSM https://t.co/8WDhUd9sMC |
| Brendon Stiles @BrendonStilesMD You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm |
 | Bob Steele @steele_bob Hi Folks, Bob here in Greensboro, NC. #lcsm |
| Jean Parks @geekbabe Research is why I’m still alive over 4 yrs after a stage IV dx #LCSM |
 | Laronica Conway @louisianagirl91 RT @BrendonStilesMD: More info about tonight’s chat at https://t.co/Lx9qF406C9 #lcsm |
 | Faces of Lung Cancer 🇺🇦 @LungCancerFaces Deana in Los Angeles here. I’ll be tweeting from the @lcsmchat account tonight. #lcsm |
| Brendon Stiles @BrendonStilesMD @steele_bob Hi Bob. Hope all is well. Thanks for joining! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm |
| #LCSM Chat @lcsmchat RT @geekbabe: Research is why I’m still alive over 4 yrs after a stage IV dx #LCSM |
| Jean Parks @geekbabe RT @BrendonStilesMD: If you are out there, please tweet #lcsm our way! |
| Brendon Stiles @BrendonStilesMD @geekbabe I love it! Glad you are here. #lcsm |
| Brendon Stiles @BrendonStilesMD We'll get started in a few minutes -- please take a moment to introduce yourselves #lcsm |
 | Deb Smith 🌻 @debsmithbeach Deb here, back in NH after a year of travel all over this amazing continent! Scans next week.... #LCSM |
| Christine Qiong Wu @wi_qiong @BrendonStilesMD Hi, Christine @wi_qiong in Canada.#LCSM |
 | Santhosh Ambika @RenoHemonc RT @g_mountzios: #ELCC2019 : @peters_solange : #ELCC2019 : @peters_solange : "Dirty" TKIs targeting multiple molecular pathways revived in the immunotherapy era! @lcsmchat #lcsm @OncoAlert #oncoalert @myESMO @IASLC https://t.co/0XoY48J7Bi |
 | Laura Greco @lgreco_ny Laura here! #lcsm |
| Brendon Stiles @BrendonStilesMD I’m your moderator Brendon Stiles, a thoracic surgeon, patient advocate, and PROUD researcher. #lcsm |
| Faces of Lung Cancer 🇺🇦 @LungCancerFaces Hey #LCSM lung cancer people. #LCSM Chat is happening now! Join us. |
 | Denise Cutlip @dennycee #lcsm Hey! Happy to be here. |
| Brendon Stiles @BrendonStilesMD @debsmithbeach thanks for joining! #lcsm |
 | Janet Freeman-Daily @JFreemanDaily Sorry I won’t be joining #LCSM Chat tonight—my flight yesterday was cancelled (thanks Denver blizzard) and my airline rebooked me to fly NOW. Have fun talking #Lungcancer research! |
 | Matthew Katz, MD 🇺🇸 💜 @subatomicdoc Good evening! Matt Katz, radiation oncologist. I hope everyone is doing well tonight :-) #lcsm |
| Brendon Stiles @BrendonStilesMD @lgreco_ny Laura!!!! #lcsm |
| Brendon Stiles @BrendonStilesMD @JFreemanDaily We will miss you! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: I’m your moderator Brendon Stiles, a thoracic surgeon, patient advocate, and PROUD researcher. #lcsm |
| #LCSM Chat @lcsmchat RT @LungCancerFaces: Hey #LCSM lung cancer people. #LCSM Chat is happening now! Join us. |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Sorry I won’t be joining #LCSM Chat tonight—my flight yesterday was cancelled (thanks Denver blizzard) and my airline rebooked me to fly NOW. Have fun talking #Lungcancer research! |
 | Matthew Steliga MD FACS @SteligaMD Hello there. Looking forward to a good discussion. Thank you! #LCSM |
| Brendon Stiles @BrendonStilesMD @subatomicdoc The one and only! Thanks for joining. #lcsm |
| Brendon Stiles @BrendonStilesMD @NarjustDuma Thanks for joining! #lcsm |
 | Flemming Rasmussen @fgrazz #lcsm |
| Brendon Stiles @BrendonStilesMD I would like to disclose conflicts – I chair @lcrf_org & have worked with @astrazeneca & @medtronic. My wife worked @pfizer and now @ppdCRO. These don’t affect opinions expressed tonight. #lcsm |
| Brendon Stiles @BrendonStilesMD In this week’s chat we hope to explore why research matters for #LungCancer patients and how to learn more about it. #lcsm |
 | Paula @lungcancer1964 RT @lcsmchat: TODAY! Education & advocacy are vital, but... “Nothing moves the needle more for lung cancer patients than research.” Join #LCSM Chat moderator @BrendonStilesMD 4/11 at 8pm ET, 5pm PT “Why research matters for Lung Cancer” Read more here: https://t.co/kH4hc49pfE… @LungCancerSux https://t.co/6p1HSI1GRm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: I would like to disclose conflicts – I chair @lcrf_org & have worked with @astrazeneca & @medtronic. My wife worked @pfizer and now @ppdCRO. These don’t affect opinions expressed tonight. #lcsm |
| Brendon Stiles @BrendonStilesMD @fgrazz Was hoping you would join! Thanks! #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @BrendonStilesMD Hi Brendon! Glad to join; I've been distracted by #radonc obscure terminology issues. This is much better :-) I hope you're well #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: In this week’s chat we hope to explore why research matters for #LungCancer patients and how to learn more about it. #lcsm |
 | ClaimCompanies.com @claimcompanies RT @JFreemanDaily: Sorry I won’t be joining #LCSM Chat tonight—my flight yesterday was cancelled (thanks Denver blizzard) and my airline rebooked me to fly NOW. Have fun talking #Lungcancer research! |
 | Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Tim here. #lcsm |
| Brendon Stiles @BrendonStilesMD #Research covers a lot of topics – cancer risk factors, early diagnosis, identifying molecular targets, developing new treatments, and more! #lcsm https://t.co/PUmks8IBrM |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @BrendonStilesMD: In this week’s chat we hope to explore why research matters for #LungCancer patients and how to learn more about it. #lcsm |
| Brendon Stiles @BrendonStilesMD #Research can include basic science, translational science, clinical studies, and population health. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: #Research covers a lot of topics – cancer risk factors, early diagnosis, identifying molecular targets, developing new treatments, and more! #lcsm https://t.co/PUmks8IBrM |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @TimAllenMDJD Hi Tim! Good to see you :-) #lcsm |
| Brendon Stiles @BrendonStilesMD We will get started soon. First, a few reminders…#lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: #Research can include basic science, translational science, clinical studies, and population health. #lcsm |
| Brendon Stiles @BrendonStilesMD Please remember to include #LCSM in ALL your tweets so the other chat participants will see them during the chat #lcsm |
 | Devika Das, MD, MSHQS @DevikaDasMD @BrendonStilesMD @lcsmchat Deep South , academic VA medical oncologist interested in equity to research access #lcsm |
| Brendon Stiles @BrendonStilesMD If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD @subatomicdoc Back atcha, @subatomicdoc! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Please remember to include #LCSM in ALL your tweets so the other chat participants will see them during the chat #lcsm |
 | Dr Samer Al-Bothaigi @SalemSamer Hi all I am Samer General surgery resident From Taiz YEMEN ,middle east Glad to join the chat #lcsm |
| Brendon Stiles @BrendonStilesMD I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to follow. #lcsm |
| Dr Samer Al-Bothaigi @SalemSamer RT @BrendonStilesMD: #Research covers a lot of topics – cancer risk factors, early diagnosis, identifying molecular targets, developing new treatments, and more! #lcsm https://t.co/PUmks8IBrM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience #lcsm |
| Brendon Stiles @BrendonStilesMD We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. #lcsm https://t.co/A1HbOLZ7MO |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to follow. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: In this week’s chat we hope to explore why research matters for #LungCancer patients and how to learn more about it. #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. #lcsm https://t.co/A1HbOLZ7MO |
| Brendon Stiles @BrendonStilesMD @DevikaDasMD @lcsmchat Thanks for joining. #lcsm |
| Brendon Stiles @BrendonStilesMD T1. Is research just for future patients, or do current patients also benefit? #lcsm |
| Laronica Conway @louisianagirl91 RT @BrendonStilesMD: T1. Is research just for future patients, or do current patients also benefit? #lcsm |
| Dr Samer Al-Bothaigi @SalemSamer RT @BrendonStilesMD: We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. #lcsm https://t.co/A1HbOLZ7MO |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. Is research just for future patients, or do current patients also benefit? #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @BrendonStilesMD: We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. #lcsm https://t.co/A1HbOLZ7MO |
| Faces of Lung Cancer 🇺🇦 @LungCancerFaces RT @BrendonStilesMD: In this week’s chat we hope to explore why research matters for #LungCancer patients and how to learn more about it. #lcsm |
| Brendon Stiles @BrendonStilesMD T1. I believe current patients can benefit. The rapid pace of progress in lung cancer brings new drugs to the clinic at a remarkable pace. #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @NarjustDuma @JFreemanDaily Definitely will miss you. Safe travels! #lcsm |
| Brendon Stiles @BrendonStilesMD T1. EGFR-, ALK-, ROS1-, BRAF-, MET-, NTRK-based drugs are great examples. So is immunotherapy. #lcsm |
| Laronica Conway @louisianagirl91 RT @BrendonStilesMD: #Research covers a lot of topics – cancer risk factors, early diagnosis, identifying molecular targets, developing new treatments, and more! #lcsm https://t.co/PUmks8IBrM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. I believe current patients can benefit. The rapid pace of progress in lung cancer brings new drugs to the clinic at a remarkable pace. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. EGFR-, ALK-, ROS1-, BRAF-, MET-, NTRK-based drugs are great examples. So is immunotherapy. #lcsm |
| Brendon Stiles @BrendonStilesMD T1. That is how we got from platinum based chemo for all to this….(from @JordiRemon) #lcsm https://t.co/nLAaZc31C5 |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @BrendonStilesMD T1. Research helps us learn what works. Depend upon the type of research, it also helps current patients #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: T1. That is how we got from platinum based chemo for all to this….(from @JordiRemon) #lcsm https://t.co/nLAaZc31C5 |
 | 🤡 @BellaCiao8th RT @BairdAM: Mesothelin targeted CAR T cell therapy #ELCC19 #lcsm #mesothelioma https://t.co/qYNf4JXWa9 |
| Jean Parks @geekbabe @BrendonStilesMD Yeah immunotherapy, @annaffarago & @MGHCancerCenter keeping me going! #LCSM |
| Flemming Rasmussen @fgrazz RT @subatomicdoc: @BrendonStilesMD T1. Research helps us learn what works. Depend upon the type of research, it also helps current patients #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @subatomicdoc: @BrendonStilesMD T1. Research helps us learn what works. Depend upon the type of research, it also helps current patients #lcsm |
| Brendon Stiles @BrendonStilesMD T1. A previous study suggested that a government backed research collaboration (SWOG) started in1950’s added 3.34 MILLION years of life for cancer patients! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. That is how we got from platinum based chemo for all to this….(from @JordiRemon) #lcsm https://t.co/nLAaZc31C5 |
| #LCSM Chat @lcsmchat RT @subatomicdoc: @BrendonStilesMD T1. Research helps us learn what works. Depend upon the type of research, it also helps current patients #lcsm |
| Bob Steele @steele_bob RT @BairdAM: Mesothelin targeted CAR T cell therapy #ELCC19 #lcsm #mesothelioma https://t.co/qYNf4JXWa9 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T1. That is how we got from platinum based chemo for all to this….(from @JordiRemon) #lcsm https://t.co/nLAaZc31C5 |
| Laronica Conway @louisianagirl91 @BrendonStilesMD @lcsmchat Dr. B! It’s Laronica in Birmingham! 😘👋🏾 I’m here kinda...multitasking! #lcsm |
| Matthew Steliga MD FACS @SteligaMD T1 I think that many patients who participate in clinical trials do benefit. They may receive treatment otherwise unavailable, and often undergo more rigorous surveillance/scrutiny which could benefit them. #LCSM |
| #LCSM Chat @lcsmchat RT @geekbabe: @BrendonStilesMD Yeah immunotherapy, @annaffarago & @MGHCancerCenter keeping me going! #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. A previous study suggested that a government backed research collaboration (SWOG) started in1950’s added 3.34 MILLION years of life for cancer patients! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T1. A previous study suggested that a government backed research collaboration (SWOG) started in1950’s added 3.34 MILLION years of life for cancer patients! #lcsm |
| Brendon Stiles @BrendonStilesMD T1. 3.34 million years of life at an estimated cost of $125 for each year of life! https://t.co/HSfiklE65P #lcsm |
 | Ian Pereira @IanJPereira @lcsmchat @wi_qiong @BrendonStilesMD Hi #lcsm. I’m a #RadOnc resident taking a break from the nomenclature fun for our hashtag project :) |
| Brendon Stiles @BrendonStilesMD @IanJPereira @lcsmchat @wi_qiong Wise choice! #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: T1. 3.34 million years of life at an estimated cost of $125 for each year of life! https://t.co/HSfiklE65P #lcsm |
| Devika Das, MD, MSHQS @DevikaDasMD @BrendonStilesMD Speaking purely of clinical trials -Certainly future patients ( no doubt) but a lot of the clinical trials are helping current patients as well. #lcsm |
 | Kurono Emon @chroemon RT @Tony_Calles: VARGADO: VARGADO: Nintedanib + Docetaxel in 3rd line after 2nd line Immunotherapy in NSCLC. Encouraging results from real clinical practice. #ELCC19 #LCSM #OncoAlert https://t.co/6zGkQjFFCT |
| Brendon Stiles @BrendonStilesMD @louisianagirl91 @lcsmchat Always love having you! #lcsm |
 | Enlightening Results 🇵🇱❤️ 🇺🇦 @GraceCordovano RT @BrendonStilesMD: Remarkable study! Potentially game changing. Congratulations to all. |
| Jean Parks @geekbabe 4 yrs covers a lot of birthdays, weddings & graduations #LCSM https://t.co/RhIY3lGubj |
| #LCSM Chat @lcsmchat RT @DevikaDasMD: @BrendonStilesMD Speaking purely of clinical trials -Certainly future patients ( no doubt) but a lot of the clinical trials are helping current patients as well. #lcsm |
| Dr Samer Al-Bothaigi @SalemSamer T1 all people ge benifit from research The change in cancer treatment may change 360 degree in the near future with genetics ,stem cell ,nanotechnology and artificial intellegence #lcsm |
| Brendon Stiles @BrendonStilesMD T1. Everyone can benefit from research. But some clinical trials are set up so that patients get “placebo” or standard of care. #lcsm |
| Ian Pereira @IanJPereira @BrendonStilesMD Interesting that #funding didn’t show up more in that wordcloud... :) #lcsm T1 |
 | Pulepuboboding @Dandelion_Wave RT @GlopesMd: Have to say that even with this, we should continue preferring chemo + IO instead of IO alone for patients with PDL1 between 1 and 49%. It is nice to have an option for patients who decline chemotherapy though. |
| Bob Steele @steele_bob RT @DevikaDasMD: @BrendonStilesMD Speaking purely of clinical trials -Certainly future patients ( no doubt) but a lot of the clinical trials are helping current patients as well. #lcsm |
| Flemming Rasmussen @fgrazz On top of @subatomicdoc 's comment 'learn what works' some areas of research allow us to how, and why, and in new ways altogether #lcsm |
 | Narjust Florez (Duma), M.D. @NarjustFlorezMD @BrendonStilesMD @lcsmchat @JordiRemon T1: Love this illustration! #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @DevikaDasMD: @BrendonStilesMD Speaking purely of clinical trials -Certainly future patients ( no doubt) but a lot of the clinical trials are helping current patients as well. #lcsm |
| Devika Das, MD, MSHQS @DevikaDasMD @BrendonStilesMD Implementation research helps quickly take novel research to disseminate them widely and in a timely manner #lcsm. ( often neglected and underfunded) |
| Brendon Stiles @BrendonStilesMD T1. Clinical and population science research are critical for understanding trends in treatment and for quality control. It helps everyone! #lcsm |
| Jean Parks @geekbabe Research gave me the beach #LCSM https://t.co/uJDeeiklVC |
| Brendon Stiles @BrendonStilesMD @IanJPereira True...the crux of the situation. #lcsm |
| Dr Samer Al-Bothaigi @SalemSamer RT @geekbabe: Research is why I’m still alive over 4 yrs after a stage IV dx #LCSM |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @fgrazz: On top of @subatomicdoc 's comment 'learn what works' some areas of research allow us to how, and why, and in new ways altogether #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. Everyone can benefit from research. But some clinical trials are set up so that patients get “placebo” or standard of care. #lcsm |
| #LCSM Chat @lcsmchat RT @fgrazz: On top of @subatomicdoc 's comment 'learn what works' some areas of research allow us to how, and why, and in new ways altogether #lcsm |
| Devika Das, MD, MSHQS @DevikaDasMD RT @BrendonStilesMD: T1. 3.34 million years of life at an estimated cost of $125 for each year of life! https://t.co/HSfiklE65P #lcsm |
| Pulepuboboding @Dandelion_Wave RT @n8pennell: To clarify, I am referring to 1-49% PDL1 expressors preferentially being treated with chemo+pembro (not all >1%) and using pembro monotherapy mostly for >=50% expressors. |
| Brendon Stiles @BrendonStilesMD T1. A patient (who has become a close friend) got diagnosed with #ALKPositive cancer and >20 brain mets the same month a new drug was approved with better brain efficacy. He is still going strong. #lcsm |
| #LCSM Chat @lcsmchat RT @DevikaDasMD: @BrendonStilesMD Implementation research helps quickly take novel research to disseminate them widely and in a timely manner #lcsm. ( often neglected and underfunded) |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. Clinical and population science research are critical for understanding trends in treatment and for quality control. It helps everyone! #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: T1. A patient (who has become a close friend) got diagnosed with #ALKPositive cancer and >20 brain mets the same month a new drug was approved with better brain efficacy. He is still going strong. #lcsm |
| Brendon Stiles @BrendonStilesMD T1. Good summary from @NCI on return on investment of cancer research: https://t.co/1eMGoy4P1Z #lcsm |
 | Christian Rolfo @ChristianRolfo #OncoAlert #LCSM |
| Bob Steele @steele_bob RT @BrendonStilesMD: T1. Good summary from @NCI on return on investment of cancer research: T1. Good summary from @NCI on return on investment of cancer research: https://t.co/1eMGoy4P1Z #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T1. Good summary from @NCI on return on investment of cancer research: T1. Good summary from @NCI on return on investment of cancer research: https://t.co/1eMGoy4P1Z #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @geekbabe: Research gave me the beach #LCSM https://t.co/uJDeeiklVC |
| Brendon Stiles @BrendonStilesMD @NarjustDuma @lcsmchat Could not agree more. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. A patient (who has become a close friend) got diagnosed with #ALKPositive cancer and >20 brain mets the same month a new drug was approved with better brain efficacy. He is still going strong. #lcsm |
| Laura Greco @lgreco_ny t1: most of the long term survivors I know are alive because of clinical trials. Even though they may "fail" from a commercial/scientific aspect they can buy patient more time. #lcsm |
| Devika Das, MD, MSHQS @DevikaDasMD @BrendonStilesMD @JordiRemon Saving this for teaching fellows #lcsm |
 | MaryAnn Brown @MARYANNBROWNMFT RT @geekbabe: @BrendonStilesMD Yeah immunotherapy, @annaffarago & @MGHCancerCenter keeping me going! #LCSM |
 | Heiko Enderling, PhD, FSMB @HeikoEnderling RT @_ShankarSiva: It's here! SABR-COMET published in @TheLancet - https://t.co/lZmAYZ3xWK - randomised trial of ablation in oligometastastic (1-5) #cancer. Double median PFS (6 mo vs 12 mo) and increased med overall survival (28 mo vs 41mo, p=0.09). @drdavidpalma et al. #lcsm #pcsm #radonc #tssmn https://t.co/kkdnHTSqrB |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. Good summary from @NCI on return on investment of cancer research: T1. Good summary from @NCI on return on investment of cancer research: https://t.co/1eMGoy4P1Z #lcsm |
 | Kathleen Skambis @KathleenSkambis #lcsm late |
| Jean Parks @geekbabe I visited @MGHCancerCenter lung cancer research lab #LCSM https://t.co/5ICV9RNfwu |
| #LCSM Chat @lcsmchat RT @lgreco_ny: t1: t1: most of the long term survivors I know are alive because of clinical trials. Even though they may "fail" from a commercial/scientific aspect they can buy patient more time. #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @BrendonStilesMD @IanJPereira @lcsmchat @wi_qiong Definitely! Good to see you Ian! #lcsm |
| Brendon Stiles @BrendonStilesMD T1. Voters want more research! Tell your elected representatives. From @AACR survey. #lcsm https://t.co/Xotv5CRKqy |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @BrendonStilesMD: T1. Good summary from @NCI on return on investment of cancer research: T1. Good summary from @NCI on return on investment of cancer research: https://t.co/1eMGoy4P1Z #lcsm |
| Devika Das, MD, MSHQS @DevikaDasMD RT @BrendonStilesMD: T1. Voters want more research! Tell your elected representatives. From @AACR survey. #lcsm https://t.co/Xotv5CRKqy |
| Dr Samer Al-Bothaigi @SalemSamer T1 i am sure that will be a revolution in csncers treatment Just like the invention of penicillin which changed the treatment amd prognosis of infections #lcsm |
| Brendon Stiles @BrendonStilesMD T2 coming.... #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. Voters want more research! Tell your elected representatives. From @AACR survey. #lcsm https://t.co/Xotv5CRKqy |
| Devika Das, MD, MSHQS @DevikaDasMD RT @BrendonStilesMD: T1. Good summary from @NCI on return on investment of cancer research: T1. Good summary from @NCI on return on investment of cancer research: https://t.co/1eMGoy4P1Z #lcsm |
| Brendon Stiles @BrendonStilesMD T2. In what areas is more research most needed for lung cancer?#lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: T1. Voters want more research! Tell your elected representatives. From @AACR survey. #lcsm https://t.co/Xotv5CRKqy |
| Pulepuboboding @Dandelion_Wave RT @Tony_Calles: VARGADO: VARGADO: Nintedanib + Docetaxel in 3rd line after 2nd line Immunotherapy in NSCLC. Encouraging results from real clinical practice. #ELCC19 #LCSM #OncoAlert https://t.co/6zGkQjFFCT |
| Jean Parks @geekbabe Research meant seeing a 1st great grandchild #LCSM https://t.co/hLpyH1eYxF |
| Deb Smith 🌻 @debsmithbeach T1. I've been in 3 clinical trials so far and 2/3 have benifitted me significantly! Happy to help future patients, thrilled to have extended my life! I've been on Tagrisso for 5 1/2 yrs, first in a trial. #LCSM |
| Laura Greco @lgreco_ny @BrendonStilesMD @AACR T1: Lung cancer research unfortunately gets short changed at the federal level. We need to emphasize how it makes monetary sense to tackle lung cancer. #lcsm |
| Brendon Stiles @BrendonStilesMD T2. Geez…I can think of about 1,000 things we need to study more! #lcsm https://t.co/T0nXag4EaN |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T2. In what areas is more research most needed for lung cancer?#lcsm |
| Brendon Stiles @BrendonStilesMD @geekbabe @MGHCancerCenter This is great. I will suggest later! #lcsm |
| Jean Parks @geekbabe RT @BrendonStilesMD: T1. That is how we got from platinum based chemo for all to this….(from @JordiRemon) #lcsm https://t.co/nLAaZc31C5 |
| Jean Parks @geekbabe RT @BrendonStilesMD: T1. A patient (who has become a close friend) got diagnosed with #ALKPositive cancer and >20 brain mets the same month a new drug was approved with better brain efficacy. He is still going strong. #lcsm |
| MaryAnn Brown @MARYANNBROWNMFT RT @BrendonStilesMD: T1. That is how we got from platinum based chemo for all to this….(from @JordiRemon) #lcsm https://t.co/nLAaZc31C5 |
| Brendon Stiles @BrendonStilesMD T2. We need to understand why so many patients develop resistance to drugs that initially work. #lcsm https://t.co/hSuGu1OjYm |
| Dr Samer Al-Bothaigi @SalemSamer What make this chat worthy Is that i see lung cancers patients share the chat Glad to see you dear patients God save you #lcsm |
| Flemming Rasmussen @fgrazz T1 = @NCI Rtn on investment - Nice summary but even they say we need 'greater progress' Only deeper into current areas, or new paths? #lcsm |
 | Kristin Ito @KAdvocate_LCAM @BrendonStilesMD Tough question...it all does! But one area in need is, small cell #LCSM |
| Laura Greco @lgreco_ny Me too... almost better question is what don't we need to study more! #lcsm |
 | Healthcare-Global😷 @HealthcareGlob1 RT @OncLive: The initial OS analysis of the MYSTIC trial of durvalumab alone or in combination with tremelimumab compared with platinum-based chemotherapy in patients with mNSCLC, may have been confounded by high rates of post-study immunotherapy #ELCC19 #lcsm https://t.co/4VicqEWjDw |
 | Frank Ingram, MD @Chucktowndoc Ingram joining a little late. Pathologist from NC. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD 2d that @BrendonStilesMD #lcsm |
| Jean Parks @geekbabe Research can give patients the gift of time #LCSM https://t.co/9PjchIbEnL |
| Bob Steele @steele_bob RT @TimAllenMDJD: 2d that @BrendonStilesMD #lcsm |
| Brendon Stiles @BrendonStilesMD T2. We need to figure out who is at risk for lung cancer, particularly among never smokers. Data from us @WeillCornell @MeyerCancer #lcsm https://t.co/mJBP6TbZ6F |
| Jean Parks @geekbabe RT @BrendonStilesMD: T1. A previous study suggested that a government backed research collaboration (SWOG) started in1950’s added 3.34 MILLION years of life for cancer patients! #lcsm |
 | Percy Lee MD @PercyLeeMD Practice changing paradigm. #sabr stereotactic ablative radiotherapy for oligometaststic disease state #lcsm #pcsm #bcsm #radonc |
| Brendon Stiles @BrendonStilesMD T2. We need to get a better handle on genetic susceptibility to lung cancer. #lcsm |
| Jean Parks @geekbabe RT @lgreco_ny: t1: t1: most of the long term survivors I know are alive because of clinical trials. Even though they may "fail" from a commercial/scientific aspect they can buy patient more time. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. In what areas is more research most needed for lung cancer?#lcsm |
| Brendon Stiles @BrendonStilesMD @Chucktowndoc Thanks for joining! #lcsm |
| #LCSM Chat @lcsmchat RT @lgreco_ny: @BrendonStilesMD @AACR T1: @BrendonStilesMD @AACR T1: Lung cancer research unfortunately gets short changed at the federal level. We need to emphasize how it makes monetary sense to tackle lung cancer. #lcsm |
| Laura Greco @lgreco_ny @BrendonStilesMD Yes! We get these fantastic results with TKIs... how lovely would it be if they lasted! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T2. We need to figure out who is at risk for lung cancer, particularly among never smokers. Data from us @WeillCornell @MeyerCancer #lcsm https://t.co/mJBP6TbZ6F |
| #LCSM Chat @lcsmchat RT @debsmithbeach: T1. I've been in 3 clinical trials so far and 2/3 have benifitted me significantly! Happy to help future patients, thrilled to have extended my life! I've been on Tagrisso for 5 1/2 yrs, first in a trial. #LCSM |
| Flemming Rasmussen @fgrazz @BrendonStilesMD T2 - drug resistance - would be nice to understand 'why' but also worth exploring areas that may be less susceptible #lcsm |
| Brendon Stiles @BrendonStilesMD T2. We need clinical and population health studies to figure out why physicians are doing such a terrible job screening at risk patients for lung cancer! #lcsm |
 | Mayte AVITIVA 13 aros en los testiculos.BRANDESING @MayteMirellaCL Each day, Dr. Cathy Pietanza is #InventingForLife and helping to improve the outlook for #lungcancer patients: mercurio us/2CyJZeB #AACR19 #LCSM |
| MaryAnn Brown @MARYANNBROWNMFT @lcsmchat #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. We need to understand why so many patients develop resistance to drugs that initially work. #lcsm https://t.co/hSuGu1OjYm |
| Ian Pereira @IanJPereira @BrendonStilesMD I have heard it described in different ways, but I believe a clinical trial often offers the best resources to patients on trial. I often wish all institutional changes were treated with as much ethical care. #lcsm T1 |
| Jean Parks @geekbabe RT @BrendonStilesMD: You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm |
| #LCSM Chat @lcsmchat RT @fgrazz: T1 = @NCI Rtn on investment - Nice summary but even they say we need 'greater progress' Only deeper into current areas, or new paths? #lcsm |
| Brendon Stiles @BrendonStilesMD T2. We need to better understand sequencing of therapy and figure out how to move targeted therapy into earlier stages. This from @JTOonline. #lcsm https://t.co/K8Sw8JaeOi |
| #LCSM Chat @lcsmchat RT @KAdvocate_LCAM: @BrendonStilesMD Tough question...it all does! But one area in need is, small cell #LCSM |
| Brendon Stiles @BrendonStilesMD RT @fgrazz: @BrendonStilesMD T2 - drug resistance - would be nice to understand 'why' but also worth exploring areas that may be less susceptible #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. We need to figure out who is at risk for lung cancer, particularly among never smokers. Data from us @WeillCornell @MeyerCancer #lcsm https://t.co/mJBP6TbZ6F |
| Flemming Rasmussen @fgrazz @BrendonStilesMD T2 - In what areas? Understanding pH and the reversed gradient is one of many #lcsm |
 | Shankar Siva @_ShankarSiva RT @PercyLeeMD: Practice changing paradigm. #sabr stereotactic ablative radiotherapy for oligometaststic disease state #lcsm #pcsm #bcsm #radonc |
| Percy Lee MD @PercyLeeMD @BrendonStilesMD T1: In a randomized study the standard treatment arm is what patients should receive as state of the art care. Under the watch of a study the quality of care should also be top notch due to extensive independent oversight #lcsm |
| Dr Samer Al-Bothaigi @SalemSamer T2 We need more researches abt quit smoking Cancers screening Treatment Cancer genetics Immunotherapy #lcsm |
 | Aparna Hegde, MD @notahedge T2: We need to improve outcomes for non-metastic NSCLC. Need screening and timely adjuvant studies. #lcsm |
| Devika Das, MD, MSHQS @DevikaDasMD @BrendonStilesMD T2 real world impact of clinical trials , boardly inclusive clinical trials ( brain Mets etc) , racial and socioeconomic disparities in lung cancer care, #lcsm besides all areas of lung cancer need more funding , dismal compared to certain other tumor types |
| Brendon Stiles @BrendonStilesMD T2. We need to better describe patient reported outcomes and side effects. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. We need to get a better handle on genetic susceptibility to lung cancer. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #JustMolecularChanges #lcsm |
| #LCSM Chat @lcsmchat RT @lgreco_ny: @BrendonStilesMD Yes! We get these fantastic results with TKIs... how lovely would it be if they lasted! #lcsm |
| #LCSM Chat @lcsmchat RT @fgrazz: @BrendonStilesMD T2 - drug resistance - would be nice to understand 'why' but also worth exploring areas that may be less susceptible #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. We need clinical and population health studies to figure out why physicians are doing such a terrible job screening at risk patients for lung cancer! #lcsm |
| Devika Das, MD, MSHQS @DevikaDasMD RT @BrendonStilesMD: T2. In what areas is more research most needed for lung cancer?#lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @JonJKruse @gdhugo @SBRT_CR @SeanSachdevMD @KimpleRandall @PercyLeeMD @DrChowdharyMD @BrendonStilesMD @IanJPereira @NicholasZaorsky @AshleyAlbertMD @DrAndrewLoblaw @BreastDocUK @_ShankarSiva @sandraturner49 @BK_radiation @UCLAHealth I wish I had more time for #lcsm and other chats. I learn a great deal that informs me on being a better cancer doctor. |
| #LCSM Chat @lcsmchat RT @IanJPereira: @BrendonStilesMD I have heard it described in different ways, but I believe a clinical trial often offers the best resources to patients on trial. I often wish all institutional changes were treated with as much ethical care. #lcsm T1 |
| Jean Parks @geekbabe I participate in every study offered to me. Because... it’s science! #LCSM |
| Brendon Stiles @BrendonStilesMD T2. We also need to understand financial toxicity of cancer care today and how that impacts patients and caregivers. #lcsm https://t.co/1Rj1lAuMTj |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. We need to better understand sequencing of therapy and figure out how to move targeted therapy into earlier stages. This from @JTOonline. #lcsm https://t.co/K8Sw8JaeOi |
| #LCSM Chat @lcsmchat RT @fgrazz: @BrendonStilesMD T2 - In what areas? Understanding pH and the reversed gradient is one of many #lcsm |
| Ian Pereira @IanJPereira @DevikaDasMD @BrendonStilesMD Any examples of what you mean by implementation research? #lcsm T1 |
| #LCSM Chat @lcsmchat RT @PercyLeeMD: @BrendonStilesMD T1: @BrendonStilesMD T1: In a randomized study the standard treatment arm is what patients should receive as state of the art care. Under the watch of a study the quality of care should also be top notch due to extensive independent oversight #lcsm |
| #LCSM Chat @lcsmchat RT @notahedge: T2: T2: We need to improve outcomes for non-metastic NSCLC. Need screening and timely adjuvant studies. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #PatientsFirst #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. We need to better describe patient reported outcomes and side effects. #lcsm |
| #LCSM Chat @lcsmchat RT @DevikaDasMD: @BrendonStilesMD T2 real world impact of clinical trials , boardly inclusive clinical trials ( brain Mets etc) , racial and socioeconomic disparities in lung cancer care, #lcsm besides all areas of lung cancer need more funding , dismal compared to certain other tumor types |
| Brendon Stiles @BrendonStilesMD @notahedge Could not agree more! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T2. We also need to understand financial toxicity of cancer care today and how that impacts patients and caregivers. #lcsm https://t.co/1Rj1lAuMTj |
 | Liz Johnson @wired4story RT @BrendonStilesMD: T2. We also need to understand financial toxicity of cancer care today and how that impacts patients and caregivers. #lcsm https://t.co/1Rj1lAuMTj |
| Laura Greco @lgreco_ny Yes! And how about a test that could be generally administered to catch cancer earlier? #lcsm |
| #LCSM Chat @lcsmchat RT @geekbabe: I participate in every study offered to me. Because... it’s science! #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. We also need to understand financial toxicity of cancer care today and how that impacts patients and caregivers. #lcsm https://t.co/1Rj1lAuMTj |
| #LCSM Chat @lcsmchat RT @IanJPereira: @DevikaDasMD @BrendonStilesMD Any examples of what you mean by implementation research? #lcsm T1 |
| Aparna Hegde, MD @notahedge This 👇. Can we achieve what we've done for breast cancer. |
| Devika Das, MD, MSHQS @DevikaDasMD @IanJPereira @BrendonStilesMD Expanding trials to real world setting - for example how to make NGS accessible in a timely and cost effective manner in rural Alabama etc #lcsm |
| #LCSM Chat @lcsmchat RT @lgreco_ny: Yes! And how about a test that could be generally administered to catch cancer earlier? #lcsm |
| Flemming Rasmussen @fgrazz @BrendonStilesMD T2 = better handle on genetic susceptibility, yes, but also to understand the cell env role that is part of the dance #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @BrendonStilesMD: T2. We also need to understand financial toxicity of cancer care today and how that impacts patients and caregivers. #lcsm https://t.co/1Rj1lAuMTj |
| Brendon Stiles @BrendonStilesMD T2. We have to figure out how to diagnose, test, and treat lung cancer better in rural communities. #NoDisparities #lcsm https://t.co/d4xxuSHFk4 |
| #LCSM Chat @lcsmchat RT @DevikaDasMD: @IanJPereira @BrendonStilesMD Expanding trials to real world setting - for example how to make NGS accessible in a timely and cost effective manner in rural Alabama etc #lcsm |
| Flemming Rasmussen @fgrazz RT @BrendonStilesMD: T2. We need to better describe patient reported outcomes and side effects. #lcsm |
| Kristin Ito @KAdvocate_LCAM @BrendonStilesMD This is HUGE! #LCSM |
| Bob Steele @steele_bob Paying it Forward is one of the benefits/effects of Clinical Trial participation #lcsm |
| #LCSM Chat @lcsmchat RT @fgrazz: @BrendonStilesMD T2 = better handle on genetic susceptibility, yes, but also to understand the cell env role that is part of the dance #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. We have to figure out how to diagnose, test, and treat lung cancer better in rural communities. #NoDisparities #lcsm https://t.co/d4xxuSHFk4 |
| Jean Parks @geekbabe @BrendonStilesMD My mom died of lung cancer & I didn’t know what that meant in terms of risk till I got sick #LCSM |
| #LCSM Chat @lcsmchat RT @steele_bob: Paying it Forward is one of the benefits/effects of Clinical Trial participation #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @lgreco_ny: Yes! And how about a test that could be generally administered to catch cancer earlier? #lcsm |
| Brendon Stiles @BrendonStilesMD T2. And we need to discover new targets. In many patients the “drivers” are still unknown. #lcsm https://t.co/qtA3cXNkwJ |
| Devika Das, MD, MSHQS @DevikaDasMD @IanJPereira @BrendonStilesMD These often include assessment of real world challenges and improving processes #lcsm |
| Brendon Stiles @BrendonStilesMD RT @steele_bob: Paying it Forward is one of the benefits/effects of Clinical Trial participation #lcsm |
 | Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @_ShankarSiva: It's here! SABR-COMET published in @TheLancet - https://t.co/lZmAYZ3xWK - randomised trial of ablation in oligometastastic (1-5) #cancer. Double median PFS (6 mo vs 12 mo) and increased med overall survival (28 mo vs 41mo, p=0.09). @drdavidpalma et al. #lcsm #pcsm #radonc #tssmn https://t.co/kkdnHTSqrB |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #Telemedicine #Telehealth #lcsm |
| Jean Parks @geekbabe RT @PercyLeeMD: @BrendonStilesMD T1: @BrendonStilesMD T1: In a randomized study the standard treatment arm is what patients should receive as state of the art care. Under the watch of a study the quality of care should also be top notch due to extensive independent oversight #lcsm |
| #LCSM Chat @lcsmchat RT @geekbabe: @BrendonStilesMD My mom died of lung cancer & I didn’t know what that meant in terms of risk till I got sick #LCSM |
| Laronica Conway @louisianagirl91 RT @steele_bob: Paying it Forward is one of the benefits/effects of Clinical Trial participation #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. And we need to discover new targets. In many patients the “drivers” are still unknown. #lcsm https://t.co/qtA3cXNkwJ |
| #LCSM Chat @lcsmchat RT @DevikaDasMD: @IanJPereira @BrendonStilesMD These often include assessment of real world challenges and improving processes #lcsm |
| Brendon Stiles @BrendonStilesMD T3 on the way.... #lcsm |
| Bob Steele @steele_bob This is such a huge issue. It has impacted friends and family members... |
| Flemming Rasmussen @fgrazz @BrendonStilesMD T2 - 1000 areas - so true...some of the funded areas need to be entirely new paths #lcsm |
| Brendon Stiles @BrendonStilesMD T3. What can researchers do to make their work more accessible to patients and advocates? #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @BrendonStilesMD: T2. We have to figure out how to diagnose, test, and treat lung cancer better in rural communities. #NoDisparities #lcsm https://t.co/d4xxuSHFk4 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #DarkSideOfTheMoon #lcsm |
| Devika Das, MD, MSHQS @DevikaDasMD RT @BrendonStilesMD: T2. And we need to discover new targets. In many patients the “drivers” are still unknown. #lcsm https://t.co/qtA3cXNkwJ |
| #LCSM Chat @lcsmchat RT @fgrazz: @BrendonStilesMD T2 - 1000 areas - so true...some of the funded areas need to be entirely new paths #lcsm |
| Devika Das, MD, MSHQS @DevikaDasMD RT @steele_bob: Paying it Forward is one of the benefits/effects of Clinical Trial participation #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. What can researchers do to make their work more accessible to patients and advocates? #lcsm |
| Devika Das, MD, MSHQS @DevikaDasMD RT @BrendonStilesMD: T2. We have to figure out how to diagnose, test, and treat lung cancer better in rural communities. #NoDisparities #lcsm https://t.co/d4xxuSHFk4 |
| Brendon Stiles @BrendonStilesMD T3. First step is to always remember that patients are the reason we do all of this! Doctors should advocate for the diseases they treat. #lcsm |
| Kathleen Skambis @KathleenSkambis RT @BrendonStilesMD: T3. What can researchers do to make their work more accessible to patients and advocates? #lcsm |
| MaryAnn Brown @MARYANNBROWNMFT RT @n8pennell: Yes it will be nice to have option of pembro for some pts with PDL1 >1% but for MOST of these NSCLC pts chemo+pembro is still the standard of care, hope that message gets out! #LCSM https://t.co/2StlDjWg4Z via @onclive |
 | Ageya Achili Diglihi @FriendsOfPipe RT @BrendonStilesMD: T2. We have to figure out how to diagnose, test, and treat lung cancer better in rural communities. #NoDisparities #lcsm https://t.co/d4xxuSHFk4 |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @BrendonStilesMD T2. I agree. We need to do a better job meeting the needs of all patients #lcsm |
| Jean Parks @geekbabe @steele_bob Knowing the researchers get info from all the blood they take from me to help others is an honor #LCSM |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @BrendonStilesMD: T3. What can researchers do to make their work more accessible to patients and advocates? #lcsm |
| Kristin Ito @KAdvocate_LCAM @BrendonStilesMD Create digestible summary slides whenever they present at conferences! #LCSM |
| Brendon Stiles @BrendonStilesMD T3. Researchers should join Twitter or other #SoMe platforms. Share your work. Explain it. Tell us why it is important. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #PatientsFirst #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. First step is to always remember that patients are the reason we do all of this! Doctors should advocate for the diseases they treat. #lcsm |
| Ian Pereira @IanJPereira RT @BrendonStilesMD: T2. We also need to understand financial toxicity of cancer care today and how that impacts patients and caregivers. #lcsm https://t.co/1Rj1lAuMTj |
| #LCSM Chat @lcsmchat RT @subatomicdoc: @BrendonStilesMD T2. I agree. We need to do a better job meeting the needs of all patients #lcsm |
| Aparna Hegde, MD @notahedge T2: Biomarkers for screening, risk stratification in adjuvant setting, for use of IO and predicting iRAEs. So much to do. Need more funding and collaborative work. #lcsm |
| Brendon Stiles @BrendonStilesMD @KAdvocate_LCAM This is key! #lcsm |
 | Dr. Miriam Knoll @MKnoll_MD RT @BrendonStilesMD: In this week’s chat we hope to explore why research matters for #LungCancer patients and how to learn more about it. #lcsm |
| Bob Steele @steele_bob RT @notahedge: T2: T2: Biomarkers for screening, risk stratification in adjuvant setting, for use of IO and predicting iRAEs. So much to do. Need more funding and collaborative work. #lcsm |
| #LCSM Chat @lcsmchat RT @KAdvocate_LCAM: @BrendonStilesMD Create digestible summary slides whenever they present at conferences! #LCSM |
 | Current Oncology @CurrentOncology Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer https://t.co/fhQkiXTIqq #nsclc #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Researchers should join Twitter or other #SoMe platforms. Share your work. Explain it. Tell us why it is important. #lcsm |
| Laronica Conway @louisianagirl91 RT @BrendonStilesMD: T3. Researchers should join Twitter or other #SoMe platforms. Share your work. Explain it. Tell us why it is important. #lcsm |
| #LCSM Chat @lcsmchat RT @notahedge: T2: T2: Biomarkers for screening, risk stratification in adjuvant setting, for use of IO and predicting iRAEs. So much to do. Need more funding and collaborative work. #lcsm |
| Brendon Stiles @BrendonStilesMD T3. I love this from @SurvivorNetTeam. Jim Allison explaining immunotherapy for patients. https://t.co/s5uT7NMTRw If a Nobel Prize winner can take the time, why can’t we all? #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: T3. I love this from @SurvivorNetTeam. Jim Allison explaining immunotherapy for patients. https://t.co/s5uT7NMTRw If a Nobel Prize winner can take the time, why can’t we all? #lcsm |
 | Andrew Chapman @andrewchap361 RT @maryam_lustberg: Important but easy survey #gerionc #asco |
| Dr Samer Al-Bothaigi @SalemSamer T3 Use open access journals Use social media #some Use hashtags #lcsm |
| Jean Parks @geekbabe So many patients are afraid of even simple clinical trials, even blood draw studies #LCSM |
| Laura Greco @lgreco_ny So important in lung cancer in particular, as there are too few survivors, and many too sick (or too stigmatized) to really make a dent in advocacy need. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. I love this from @SurvivorNetTeam. Jim Allison explaining immunotherapy for patients. https://t.co/s5uT7NMTRw If a Nobel Prize winner can take the time, why can’t we all? #lcsm |
| Brendon Stiles @BrendonStilesMD T3. For scientific manuscripts, visual abstracts are awesome and easy to disseminate. #lcsm https://t.co/Z9Ld0yEKok |
| Jean Parks @geekbabe RT @BrendonStilesMD: T2. We have to figure out how to diagnose, test, and treat lung cancer better in rural communities. #NoDisparities #lcsm https://t.co/d4xxuSHFk4 |
 | Samuel Chao @SamuelChaoMD RT @JAMAOnc: BEWARE of high risk of combination of anti-angiogenic agents w SBRT to “ultra-central” chest tumors abutting proximal bronchial tree or esophagus assoc’d w 22% rate of grade >3 toxicity & 11% fatality rate https://t.co/FKUbLbQkje #RadOnc #LCSM |
| Dr Samer Al-Bothaigi @SalemSamer RT @BrendonStilesMD: T3. I love this from @SurvivorNetTeam. Jim Allison explaining immunotherapy for patients. https://t.co/s5uT7NMTRw If a Nobel Prize winner can take the time, why can’t we all? #lcsm |
| Jean Parks @geekbabe RT @BrendonStilesMD: T2. We also need to understand financial toxicity of cancer care today and how that impacts patients and caregivers. #lcsm https://t.co/1Rj1lAuMTj |
| Brendon Stiles @BrendonStilesMD T3. Bring patients to your labs or to research days. #lcsm |
| Dr Samer Al-Bothaigi @SalemSamer RT @BrendonStilesMD: T3. Researchers should join Twitter or other #SoMe platforms. Share your work. Explain it. Tell us why it is important. #lcsm |
| Brendon Stiles @BrendonStilesMD @geekbabe This is a failure on researchers part! #lcsm |
| Kathleen Skambis @KathleenSkambis T3. In addition to costs of treatment, trial costs of note to patients include simple things, like parking costs. #lcsm |
| Ian Pereira @IanJPereira RT @BrendonStilesMD: T1. Voters want more research! Tell your elected representatives. From @AACR survey. #lcsm https://t.co/Xotv5CRKqy |
| Brendon Stiles @BrendonStilesMD T3. When we had a #FreeToBreathe @lcrf_org lab tour, both patients and researchers learned from each other! #lcsm https://t.co/BAQmFrvxIn |
| Kristin Ito @KAdvocate_LCAM @BrendonStilesMD Also...think about including patient advocates in review process for patient related surveys. #LCSM |
| Laura Greco @lgreco_ny t3 how about making scientific articles actually available online instead of through paywall? #lcsm |
| #LCSM Chat @lcsmchat RT @lgreco_ny: So important in lung cancer in particular, as there are too few survivors, and many too sick (or too stigmatized) to really make a dent in advocacy need. #lcsm |
| Jean Parks @geekbabe @BrendonStilesMD Yeah, I’m still working but at greatly reduced income. Cancer costs $, energy & lives #LCSM |
| Devika Das, MD, MSHQS @DevikaDasMD @BrendonStilesMD @lcsmchat T3 Present unbiased opinions via social media ( free of conflict ) , availability of experts for second opinions via telemedicine #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. For scientific manuscripts, visual abstracts are awesome and easy to disseminate. #lcsm https://t.co/Z9Ld0yEKok |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Bring patients to your labs or to research days. #lcsm |
| Brendon Stiles @BrendonStilesMD T3. This is a great video by the way – how patients help researchers and why you need to Make Noise! #lcsm |
| Flemming Rasmussen @fgrazz @BrendonStilesMD T3 - means for better access to research/researchers. Change the reward structure & secrecy to openness/collaboration #lcsm |
| Devika Das, MD, MSHQS @DevikaDasMD RT @KAdvocate_LCAM: @BrendonStilesMD Also...think about including patient advocates in review process for patient related surveys. #LCSM |
| #LCSM Chat @lcsmchat RT @KathleenSkambis: T3. In addition to costs of treatment, trial costs of note to patients include simple things, like parking costs. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. When we had a #FreeToBreathe @lcrf_org lab tour, both patients and researchers learned from each other! #lcsm https://t.co/BAQmFrvxIn |
| Denise Cutlip @dennycee Education. I still see pts who believe clinical trials are only last resort. Concept of chemo naive not in radar. #lcsm |
| #LCSM Chat @lcsmchat RT @KAdvocate_LCAM: @BrendonStilesMD Also...think about including patient advocates in review process for patient related surveys. #LCSM |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @BrendonStilesMD T3. I agree for academics. It's different for generalists like me. I do try to advocate for all my patients, but it differs from more specialized oncology professionals. It still may be disease-specific but different strategies for advocacy #lcsm |
| #LCSM Chat @lcsmchat RT @lgreco_ny: t3 how about making scientific articles actually available online instead of through paywall? #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: T3. For scientific manuscripts, visual abstracts are awesome and easy to disseminate. #lcsm https://t.co/Z9Ld0yEKok |
| Brendon Stiles @BrendonStilesMD T3. I love it when groups - @lcrf_org, @LUNGevity, @theALCF, @lcaorg – bring patients, advocates, and researchers together. #lcsm |
| #LCSM Chat @lcsmchat RT @DevikaDasMD: @BrendonStilesMD @lcsmchat T3 Present unbiased opinions via social media ( free of conflict ) , availability of experts for second opinions via telemedicine #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. This is a great video by the way – how patients help researchers and why you need to Make Noise! #lcsm |
 | Anita Figueras @scifiknitter Anita from northern NY joining late. A cofounder of the EGFR Resisters, which has 2 active patient-driven research projects. #LCSM |
| #LCSM Chat @lcsmchat RT @fgrazz: @BrendonStilesMD T3 - means for better access to research/researchers. Change the reward structure & secrecy to openness/collaboration #lcsm |
| Brendon Stiles @BrendonStilesMD @KAdvocate_LCAM More on this later! #lcsm |
| #LCSM Chat @lcsmchat RT @dennycee: Education. I still see pts who believe clinical trials are only last resort. Concept of chemo naive not in radar. #lcsm |
| #LCSM Chat @lcsmchat RT @subatomicdoc: @BrendonStilesMD T3. I agree for academics. It's different for generalists like me. I do try to advocate for all my patients, but it differs from more specialized oncology professionals. It still may be disease-specific but different strategies for advocacy #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. I love it when groups - @lcrf_org, @LUNGevity, @theALCF, @lcaorg – bring patients, advocates, and researchers together. #lcsm |
| Dr Samer Al-Bothaigi @SalemSamer T3 however we want some trustworthy social media accounts that fight rumors snd dussiminate trusted and true kniwledges #SoMe4Surgery #lcsm |
| Anita Figueras @scifiknitter RT @BrendonStilesMD: T3. I love this from @SurvivorNetTeam. Jim Allison explaining immunotherapy for patients. https://t.co/s5uT7NMTRw If a Nobel Prize winner can take the time, why can’t we all? #lcsm |
| Laura Greco @lgreco_ny t3 Fund scholarships so patients can go to medical conferences. Getting a scholarship can feel like winning the lotto because it is so rare. #lcsm |
| Aparna Hegde, MD @notahedge T3: so much can be done. 1.Share your work on #SoMe 2.Engage patient advocates when designing trials. 3.Large professional organizations should make conferences more accessible to patients and caregivers. 4.Important papers behind paywalls- this one is the toughest. #lcsm |
| Brendon Stiles @BrendonStilesMD T3. Pushing for open access publication is key. Journals could do better sharing content. From @PLOSONE https://t.co/We2J5mqJe8 #lcsm |
| Dr Samer Al-Bothaigi @SalemSamer RT @BrendonStilesMD: T3. For scientific manuscripts, visual abstracts are awesome and easy to disseminate. #lcsm https://t.co/Z9Ld0yEKok |
| Kristin Ito @KAdvocate_LCAM @BrendonStilesMD @lcrf_org @LUNGevity @TheALCF @LCAorg Yes! Each group brings a unique expertise! #LCSM |
 | Kimberley H Geissler @khgeissler @lgreco_ny Many researchers happy to share if you email them for a copy. Researchers, respond to these requests!! #lcsm |
| Brendon Stiles @BrendonStilesMD @SalemSamer We definitely need a strong voice in this space. #lcsm |
| Devika Das, MD, MSHQS @DevikaDasMD RT @lgreco_ny: t3 how about making scientific articles actually available online instead of through paywall? #lcsm |
| #LCSM Chat @lcsmchat RT @lgreco_ny: t3 Fund scholarships so patients can go to medical conferences. Getting a scholarship can feel like winning the lotto because it is so rare. #lcsm |
| Flemming Rasmussen @fgrazz @BrendonStilesMD that is a great example #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Pushing for open access publication is key. Journals could do better sharing content. From @PLOSONE https://t.co/We2J5mqJe8 #lcsm |
| #LCSM Chat @lcsmchat RT @notahedge: T3: T3: so much can be done. 1.Share your work on #SoMe 2.Engage patient advocates when designing trials. 3.Large professional organizations should make conferences more accessible to patients and caregivers. 4.Important papers behind paywalls- this one is the toughest. #lcsm |
| #LCSM Chat @lcsmchat RT @khgeissler: @lgreco_ny Many researchers happy to share if you email them for a copy. Researchers, respond to these requests!! #lcsm |
| Jean Parks @geekbabe @BrendonStilesMD @MGHCancerCenter The tour was amazing! I even met Dr Alice Shaw #LCSM https://t.co/8oVln1zn7c |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @notahedge: T3: T3: so much can be done. 1.Share your work on #SoMe 2.Engage patient advocates when designing trials. 3.Large professional organizations should make conferences more accessible to patients and caregivers. 4.Important papers behind paywalls- this one is the toughest. #lcsm |
| Dr Samer Al-Bothaigi @SalemSamer RT @BrendonStilesMD: @SalemSamer We definitely need a strong voice in this space. #lcsm |
| #LCSM Chat @lcsmchat RT @SalemSamer: T3 however we want some trustworthy social media accounts that fight rumors snd dussiminate trusted and true kniwledges #SoMe4Surgery #lcsm |
| Devika Das, MD, MSHQS @DevikaDasMD RT @lgreco_ny: t3 Fund scholarships so patients can go to medical conferences. Getting a scholarship can feel like winning the lotto because it is so rare. #lcsm |
| Brendon Stiles @BrendonStilesMD @lgreco_ny Yes!From @PLOSONE https://t.co/We2J5mqJe8 #lcsm |
| Laura Greco @lgreco_ny Involve patients in decisions on what research to fund, even internally. #lcsm |
| Bob Steele @steele_bob Absolutely agree Laura! This is a high priority issue! |
| Ian Pereira @IanJPereira RT @TimAllenMDJD: #Telemedicine #Telehealth #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @lgreco_ny Yes!From @PLOSONE https://t.co/We2J5mqJe8 #lcsm |
| #LCSM Chat @lcsmchat RT @lgreco_ny: Involve patients in decisions on what research to fund, even internally. #lcsm |
| Brendon Stiles @BrendonStilesMD @khgeissler @lgreco_ny This is definitely true. Don't hesitate to ask and also ask what they think is important about the research! #lcsm |
| Kathleen Skambis @KathleenSkambis T3: lawyers have pubs that publish annual surveys of important cases in key areas. Do researchers/oncologists do this? If so, help make them accessible to patients. #lcsm |
| Ian Pereira @IanJPereira @TimAllenMDJD And improve stickiness to follow-up/surveillance. #lcsm T2 |
| Christine Qiong Wu @wi_qiong @lgreco_ny Agree. #LCSM |
| Laura Greco @lgreco_ny If you can find their email address....and many patients are very hesitant to email a doctor. #lcsm |
 | Tim Kruser @TimothyKruserMD RT @_ShankarSiva: It's here! SABR-COMET published in @TheLancet - https://t.co/lZmAYZ3xWK - randomised trial of ablation in oligometastastic (1-5) #cancer. Double median PFS (6 mo vs 12 mo) and increased med overall survival (28 mo vs 41mo, p=0.09). @drdavidpalma et al. #lcsm #pcsm #radonc #tssmn https://t.co/kkdnHTSqrB |
| Brendon Stiles @BrendonStilesMD @lgreco_ny My sense is that we are getting better at this. But more to do. #lcsm |
| Dr Samer Al-Bothaigi @SalemSamer T3 consider how social media can fight smoking This only can do a lot about lung cancer #lcsm |
| Anita Figueras @scifiknitter @KAdvocate_LCAM @BrendonStilesMD Include patients in the design of surveys, not just in the review. We can write valid and understandable questions. #lcsm |
| Anita Figueras @scifiknitter RT @lgreco_ny: t3 how about making scientific articles actually available online instead of through paywall? #lcsm |
 | Geoff Hugo @gdhugo @BrendonStilesMD T3. Listen to them. Best part of our dept. retreat is the patient invited to share their experience each year. Helps us non-physicians prioritize and focus our work on what’s important to the patient. #lcsm |
| Christine Qiong Wu @wi_qiong @BrendonStilesMD @PLOSONE Agree. #LCSM |
| Brendon Stiles @BrendonStilesMD @EdenLake Thanks for being here! #lcsm |
 | Lung Cancer #1 cancer killer of women @VirginiaMByrne #LCSM |
| Aparna Hegde, MD @notahedge RT @scifiknitter: @KAdvocate_LCAM @BrendonStilesMD Include patients in the design of surveys, not just in the review. We can write valid and understandable questions. #lcsm |
| #LCSM Chat @lcsmchat RT @KathleenSkambis: T3: T3: lawyers have pubs that publish annual surveys of important cases in key areas. Do researchers/oncologists do this? If so, help make them accessible to patients. #lcsm |
| #LCSM Chat @lcsmchat RT @IanJPereira: @TimAllenMDJD And improve stickiness to follow-up/surveillance. #lcsm T2 |
| Jean Parks @geekbabe Lung cancer patients... we do matter! Research is vital #LCSM https://t.co/IL7xVEAzM8 |
| Kristin Ito @KAdvocate_LCAM @scifiknitter @BrendonStilesMD Absolutely agree! #LCSM |
| #LCSM Chat @lcsmchat RT @lgreco_ny: If you can find their email address....and many patients are very hesitant to email a doctor. #lcsm |
| Ian Pereira @IanJPereira T2 - more creative ways to fund more studies, including in radiation treatment for #LungCancer. #RTDrugCombo? #lcsm #RadOnc |
| Anita Figueras @scifiknitter RT @dennycee: Education. I still see pts who believe clinical trials are only last resort. Concept of chemo naive not in radar. #lcsm |
| #LCSM Chat @lcsmchat RT @scifiknitter: @KAdvocate_LCAM @BrendonStilesMD Include patients in the design of surveys, not just in the review. We can write valid and understandable questions. #lcsm |
| #LCSM Chat @lcsmchat RT @gdhugo: @BrendonStilesMD T3. Listen to them. Best part of our dept. retreat is the patient invited to share their experience each year. Helps us non-physicians prioritize and focus our work on what’s important to the patient. #lcsm |
| Laura Greco @lgreco_ny Yes! All of this and more! #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @gdhugo: @BrendonStilesMD T3. Listen to them. Best part of our dept. retreat is the patient invited to share their experience each year. Helps us non-physicians prioritize and focus our work on what’s important to the patient. #lcsm |
| Brendon Stiles @BrendonStilesMD Rolling onto T4 in another few minutes... #lcsm |
| Dr Samer Al-Bothaigi @SalemSamer T3 doctors and patients can cooperate to fight smoking by using social media #lcsm |
| Jean Parks @geekbabe RT @IanJPereira: T2 - more creative ways to fund more studies, including in radiation treatment for #LungCancer. #RTDrugCombo? #lcsm #RadOnc |
| #LCSM Chat @lcsmchat RT @IanJPereira: T2 - more creative ways to fund more studies, including in radiation treatment for #LungCancer. #RTDrugCombo? #lcsm #RadOnc |
| #LCSM Chat @lcsmchat RT @lgreco_ny: Yes! All of this and more! #lcsm |
| Kimberley H Geissler @khgeissler @lgreco_ny Agree on all points, although generally corresponding author's email is listed with the abstract so may be easier to find. (This is obviously a bandaid, not a good solution to the problem of paywalled research!) #lcsm |
| Jean Parks @geekbabe RT @gdhugo: @BrendonStilesMD T3. Listen to them. Best part of our dept. retreat is the patient invited to share their experience each year. Helps us non-physicians prioritize and focus our work on what’s important to the patient. #lcsm |
| Jean Parks @geekbabe RT @scifiknitter: @KAdvocate_LCAM @BrendonStilesMD Include patients in the design of surveys, not just in the review. We can write valid and understandable questions. #lcsm |
| Flemming Rasmussen @fgrazz @lgreco_ny too true (open access would assist greatly) but you'd be surprised at what is accessible through NCBI and researchgate... #lcsm |
| Jean Parks @geekbabe RT @lgreco_ny: If you can find their email address....and many patients are very hesitant to email a doctor. #lcsm |
| Aparna Hegde, MD @notahedge RT @BrendonStilesMD: T3. I love it when groups - @lcrf_org, @LUNGevity, @theALCF, @lcaorg – bring patients, advocates, and researchers together. #lcsm |
 | Dr. Jennifer McQuade @mcquadeMDLAc Very important study showing benefit of Stereotactic radioablation in oligometastatic cancer. Congrats to the investigators on conducting a randomized trial to address this question! |
| Bob Steele @steele_bob RT @khgeissler: @lgreco_ny Agree on all points, although generally corresponding author's email is listed with the abstract so may be easier to find. (This is obviously a bandaid, not a good solution to the problem of paywalled research!) #lcsm |
| Kristin Ito @KAdvocate_LCAM @wi_qiong @BrendonStilesMD @PLOSONE IASLC offers complimentary membership to patients/survivors and caregivers, which provides (free) online access to the JTO. #LCSM |
| Anita Figueras @scifiknitter RT @lgreco_ny: Yes! All of this and more! #lcsm |
| Aparna Hegde, MD @notahedge RT @KAdvocate_LCAM: @wi_qiong @BrendonStilesMD @PLOSONE IASLC offers complimentary membership to patients/survivors and caregivers, which provides (free) online access to the JTO. #LCSM |
 | DrJoeBovi @DrJoeBovi RT @_ShankarSiva: It's here! SABR-COMET published in @TheLancet - https://t.co/lZmAYZ3xWK - randomised trial of ablation in oligometastastic (1-5) #cancer. Double median PFS (6 mo vs 12 mo) and increased med overall survival (28 mo vs 41mo, p=0.09). @drdavidpalma et al. #lcsm #pcsm #radonc #tssmn https://t.co/kkdnHTSqrB |
| Bob Steele @steele_bob RT @KAdvocate_LCAM: @wi_qiong @BrendonStilesMD @PLOSONE IASLC offers complimentary membership to patients/survivors and caregivers, which provides (free) online access to the JTO. #LCSM |
| Brendon Stiles @BrendonStilesMD T4. What is the @IASLC STARS program and why are programs that train patients and advocates important? #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @KAdvocate_LCAM: @wi_qiong @BrendonStilesMD @PLOSONE IASLC offers complimentary membership to patients/survivors and caregivers, which provides (free) online access to the JTO. #LCSM |
| #LCSM Chat @lcsmchat RT @khgeissler: @lgreco_ny Agree on all points, although generally corresponding author's email is listed with the abstract so may be easier to find. (This is obviously a bandaid, not a good solution to the problem of paywalled research!) #lcsm |
| #LCSM Chat @lcsmchat RT @fgrazz: @lgreco_ny too true (open access would assist greatly) but you'd be surprised at what is accessible through NCBI and researchgate... #lcsm |
 | OncLive.com @OncLive PROs according to PD-L1 expression did not show clinically meaningful differences in QoL with either durvalumab or placebo in patients with stage III NSCLC who have not progressed following chemoradiotherapy #ELCC19 #lcsm https://t.co/335o5TDPS8 |
| Ian Pereira @IanJPereira @KAdvocate_LCAM @BrendonStilesMD And tweet or otherwise openly share the refined insights (e.g. on #lcsm). #OpenAccess |
| #LCSM Chat @lcsmchat RT @KAdvocate_LCAM: @wi_qiong @BrendonStilesMD @PLOSONE IASLC offers complimentary membership to patients/survivors and caregivers, which provides (free) online access to the JTO. #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. What is the @IASLC STARS program and why are programs that train patients and advocates important? #lcsm |
| Jean Parks @geekbabe My Oncologist says not all patients are as involved in following the science as I am, this needs to change #LCSM |
| Ian Pereira @IanJPereira RT @BrendonStilesMD: T3. Researchers should join Twitter or other #SoMe platforms. Share your work. Explain it. Tell us why it is important. #lcsm |
| Brendon Stiles @BrendonStilesMD T4. It stands for Supportive Training for Advocates on Research and Science (STARS). Great concept, right?!?! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T4. What is the @IASLC STARS program and why are programs that train patients and advocates important? #lcsm |
| Laura Greco @lgreco_ny @KAdvocate_LCAM @wi_qiong @BrendonStilesMD @PLOSONE @IASLC really is a leader in this regard! #lcsm |
| Matthew Steliga MD FACS @SteligaMD t3: We have a research open house type event @uamscancer for community supporters- where researchers have posters but also lay summaries with each one. It’s really well received. A lay summary of key findings can demystify the research and open doors for understanding. #LCSM |
| Dr Samer Al-Bothaigi @SalemSamer T3 I luv the passion of lung cancer patients that mk them active and share this chat I respect you #lcsm |
| Brendon Stiles @BrendonStilesMD T4. Here is a great link describing the program. https://t.co/pdvLflndTr #lcsm |
| Bob Steele @steele_bob RT @SteligaMD: t3: t3: We have a research open house type event @uamscancer for community supporters- where researchers have posters but also lay summaries with each one. It’s really well received. A lay summary of key findings can demystify the research and open doors for understanding. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @SteligaMD: t3: t3: We have a research open house type event @uamscancer for community supporters- where researchers have posters but also lay summaries with each one. It’s really well received. A lay summary of key findings can demystify the research and open doors for understanding. #LCSM |
| #LCSM Chat @lcsmchat RT @IanJPereira: @KAdvocate_LCAM @BrendonStilesMD And tweet or otherwise openly share the refined insights (e.g. on #lcsm). #OpenAccess |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @IanJPereira: T2 - more creative ways to fund more studies, including in radiation treatment for #LungCancer. #RTDrugCombo? #lcsm #RadOnc |
| Aparna Hegde, MD @notahedge RT @SteligaMD: t3: t3: We have a research open house type event @uamscancer for community supporters- where researchers have posters but also lay summaries with each one. It’s really well received. A lay summary of key findings can demystify the research and open doors for understanding. #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. It stands for Supportive Training for Advocates on Research and Science (STARS). Great concept, right?!?! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T4. It stands for Supportive Training for Advocates on Research and Science (STARS). Great concept, right?!?! #lcsm |
| Jean Parks @geekbabe RT @SteligaMD: t3: t3: We have a research open house type event @uamscancer for community supporters- where researchers have posters but also lay summaries with each one. It’s really well received. A lay summary of key findings can demystify the research and open doors for understanding. #LCSM |
| Bob Steele @steele_bob RT @BrendonStilesMD: T4. Here is a great link describing the program. https://t.co/pdvLflndTr #lcsm |
| Jean Parks @geekbabe RT @BrendonStilesMD: T4. Here is a great link describing the program. https://t.co/pdvLflndTr #lcsm |
| Brendon Stiles @BrendonStilesMD @lgreco_ny T4. I give lots of credit to @iaslc for recognizing the need to better train advocates and patients on research and science! #lcsm |
| Dr Samer Al-Bothaigi @SalemSamer RT @geekbabe: My Oncologist says not all patients are as involved in following the science as I am, this needs to change #LCSM |
| Liz Johnson @wired4story @notahedge Yes! This precisely! #lcsm #bcsm |
| Kristin Ito @KAdvocate_LCAM @BrendonStilesMD @IASLC Many patients are eager to learn beyond their diagnosis and advocate for the lung cancer community as a whole! #LCSM |
| Brendon Stiles @BrendonStilesMD T4. Some goals: Educate about scientific process and how to read and interpret research articles. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Absolutely #lcsm |
| Anita Figueras @scifiknitter RT @BrendonStilesMD: @lgreco_ny T4. I give lots of credit to @iaslc for recognizing the need to better train advocates and patients on research and science! #lcsm |
 | Mersiha Hadziahmetovic MD @MHadziMD RT @_ShankarSiva: It's here! SABR-COMET published in @TheLancet - https://t.co/lZmAYZ3xWK - randomised trial of ablation in oligometastastic (1-5) #cancer. Double median PFS (6 mo vs 12 mo) and increased med overall survival (28 mo vs 41mo, p=0.09). @drdavidpalma et al. #lcsm #pcsm #radonc #tssmn https://t.co/kkdnHTSqrB |
| #LCSM Chat @lcsmchat RT @lgreco_ny: @KAdvocate_LCAM @wi_qiong @BrendonStilesMD @PLOSONE @IASLC really is a leader in this regard! #lcsm |
| Kristin Ito @KAdvocate_LCAM RT @lgreco_ny: @KAdvocate_LCAM @wi_qiong @BrendonStilesMD @PLOSONE @IASLC really is a leader in this regard! #lcsm |
| Lung Cancer #1 cancer killer of women @VirginiaMByrne T3 #lcsm I just had the honor of touring Aaron Hata's lab at MGH. My eyes were opened! |
| #LCSM Chat @lcsmchat RT @SteligaMD: t3: t3: We have a research open house type event @uamscancer for community supporters- where researchers have posters but also lay summaries with each one. It’s really well received. A lay summary of key findings can demystify the research and open doors for understanding. #LCSM |
| Brendon Stiles @BrendonStilesMD T4. Goal: Teaching patients/advocates to communicate importance of lung cancer science and research. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Here is a great link describing the program. https://t.co/pdvLflndTr #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @lgreco_ny T4. I give lots of credit to @iaslc for recognizing the need to better train advocates and patients on research and science! #lcsm |
| Brendon Stiles @BrendonStilesMD T4. Important because we HAVE to have most important stakeholders – PATIENTS – at the table when making research decisions. #lcsm |
| #LCSM Chat @lcsmchat RT @KAdvocate_LCAM: @BrendonStilesMD @IASLC Many patients are eager to learn beyond their diagnosis and advocate for the lung cancer community as a whole! #LCSM |
| Aparna Hegde, MD @notahedge @IASLC STAR program for patient advocates. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Some goals: T4. Some goals: Educate about scientific process and how to read and interpret research articles. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T4. Goal: T4. Goal: Teaching patients/advocates to communicate importance of lung cancer science and research. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Goal: T4. Goal: Teaching patients/advocates to communicate importance of lung cancer science and research. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Important because we HAVE to have most important stakeholders – PATIENTS – at the table when making research decisions. #lcsm |
| Anita Figueras @scifiknitter RT @BrendonStilesMD: T4. Some goals: T4. Some goals: Educate about scientific process and how to read and interpret research articles. #lcsm |
| Kristin Ito @KAdvocate_LCAM YES! YES! YES! #LCSM |
| Brendon Stiles @BrendonStilesMD T4. We also need patients to tell the story of WHY and HOW research helped them. #LungCancer funding still lags behind. Has to change. #lcsm https://t.co/Y7eds6skik |
| Anita Figueras @scifiknitter RT @BrendonStilesMD: T4. Goal: T4. Goal: Teaching patients/advocates to communicate importance of lung cancer science and research. #lcsm |
| Devika Das, MD, MSHQS @DevikaDasMD RT @BrendonStilesMD: T4. Here is a great link describing the program. https://t.co/pdvLflndTr #lcsm |
| Anita Figueras @scifiknitter RT @BrendonStilesMD: T4. Important because we HAVE to have most important stakeholders – PATIENTS – at the table when making research decisions. #lcsm |
| Dr Samer Al-Bothaigi @SalemSamer RT @SalemSamer: T3 however we want some trustworthy social media accounts that fight rumors snd dussiminate trusted and true kniwledges #SoMe4Surgery #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T4. We also need patients to tell the story of WHY and HOW research helped them. #LungCancer funding still lags behind. Has to change. #lcsm https://t.co/Y7eds6skik |
 | Arthur sharp @Arthurs19562936 RT @Merck: Each day, Dr. Cathy Pietanza is #InventingForLife and helping to improve the outlook for #lungcancer patients: Each day, Dr. Cathy Pietanza is #InventingForLife and helping to improve the outlook for #lungcancer patients: https://t.co/4leTbR7GCB #AACR19 #LCSM https://t.co/SWNXgin9v5 |
 | Efraín J. Sánchez Angarita @efrasanchez RT @OncLive: BREAKING: BREAKING: Dr. Anna Farago on the @US_FDA Approval of Pembrolizumab for Lower PD-1 Cutoff #NSCLC #lcsm @MGHCancerCenter https://t.co/xHz6DOMNIl |
| Kathleen Skambis @KathleenSkambis T4 should include discussions of how scientists view research results. Sometimes, appropriately, in ways more limited than many patients& advocates expect. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. We also need patients to tell the story of WHY and HOW research helped them. #LungCancer funding still lags behind. Has to change. #lcsm https://t.co/Y7eds6skik |
| Ian Pereira @IanJPereira @BrendonStilesMD T3: Perhaps recognize (and be recognized for) education - for peers, patients, public, and beyond. #lcsm #meded |
| Kristin Ito @KAdvocate_LCAM @BrendonStilesMD The patient voice is so important to help guide research! STARS aims to build the patient voice UP! #LCSM |
| Brendon Stiles @BrendonStilesMD Coming to T5. #lcsm |
| Jean Parks @geekbabe @IanJPereira I have 1 stable tumor, said to the Onc, can’t you use focus radiation or freeze & surgically remove it now? I do my reading 😀 #LCSM |
| #LCSM Chat @lcsmchat RT @KAdvocate_LCAM: @BrendonStilesMD The patient voice is so important to help guide research! STARS aims to build the patient voice UP! #LCSM |
| #LCSM Chat @lcsmchat RT @KathleenSkambis: T4 should include discussions of how scientists view research results. Sometimes, appropriately, in ways more limited than many patients& advocates expect. #lcsm |
| Aparna Hegde, MD @notahedge This is important in spreading awareness about research, trial participation, fund raising and design of better research. #lcsm |
| Anita Figueras @scifiknitter RT @BrendonStilesMD: T4. We also need patients to tell the story of WHY and HOW research helped them. #LungCancer funding still lags behind. Has to change. #lcsm https://t.co/Y7eds6skik |
| #LCSM Chat @lcsmchat RT @IanJPereira: @BrendonStilesMD T3: @BrendonStilesMD T3: Perhaps recognize (and be recognized for) education - for peers, patients, public, and beyond. #lcsm #meded |
| Jean Parks @geekbabe RT @BrendonStilesMD: T3. Researchers should join Twitter or other #SoMe platforms. Share your work. Explain it. Tell us why it is important. #lcsm |
| Brendon Stiles @BrendonStilesMD T5. How can patients and advocates get more involved with research?#lcsm |
| Christine Qiong Wu @wi_qiong @BrendonStilesMD Agree.#lcsm |
| Devika Das, MD, MSHQS @DevikaDasMD @BrendonStilesMD @lcsmchat @CoC_ACS needs to make inclusion of patient advocates on the cancer committees mandatory as required members to maintain accreditation #lcsm |
| Dr Samer Al-Bothaigi @SalemSamer RT @KAdvocate_LCAM: @BrendonStilesMD The patient voice is so important to help guide research! STARS aims to build the patient voice UP! #LCSM |
| #LCSM Chat @lcsmchat RT @notahedge: This is important in spreading awareness about research, trial participation, fund raising and design of better research. #lcsm |
| Brendon Stiles @BrendonStilesMD T5. Scan the literature and ask questions. Reach out to authors, especially those on social media. They want the dialogue too. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. How can patients and advocates get more involved with research?#lcsm |
| Jean Parks @geekbabe RT @KAdvocate_LCAM: @BrendonStilesMD The patient voice is so important to help guide research! STARS aims to build the patient voice UP! #LCSM |
| Jean Parks @geekbabe RT @BrendonStilesMD: T4. We also need patients to tell the story of WHY and HOW research helped them. #LungCancer funding still lags behind. Has to change. #lcsm https://t.co/Y7eds6skik |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T5. How can patients and advocates get more involved with research?#lcsm |
| Brendon Stiles @BrendonStilesMD T5. Several websites try to update news from the field and to put it in common language. https://t.co/0fkUOn6Xpz #lcsm |
| Laura Greco @lgreco_ny RT @DevikaDasMD: @BrendonStilesMD @lcsmchat @CoC_ACS needs to make inclusion of patient advocates on the cancer committees mandatory as required members to maintain accreditation #lcsm |
| Ryo. Oncology @OncologyRyo RT @Tony_Calles: Chemotherapy looks better for low bTMB based on OAK/POPLAR trial in 2nd line NSCLC #ELCC19 #LCSM #OncoAlert https://t.co/Qgmj29v6qf |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T5. Several websites try to update news from the field and to put it in common language. https://t.co/0fkUOn6Xpz #lcsm |
| Brendon Stiles @BrendonStilesMD T5. @SurvivorNetTeam does a good job of keeping an eye on scientific advances and explaining them in lay terms. https://t.co/Hy924wM24j #lcsm |
| Lung Cancer #1 cancer killer of women @VirginiaMByrne #lcsm At MSKCC it's against the "rules" to email docs or nurses. I find that so backwards. |
| Flemming Rasmussen @fgrazz @BrendonStilesMD Indeed...some of the targets may be already well known pathways..tackled from entirely new approaches #LCSM |
| #LCSM Chat @lcsmchat RT @DevikaDasMD: @BrendonStilesMD @lcsmchat @CoC_ACS needs to make inclusion of patient advocates on the cancer committees mandatory as required members to maintain accreditation #lcsm |
| Aparna Hegde, MD @notahedge RT @BrendonStilesMD: T5. Scan the literature and ask questions. Reach out to authors, especially those on social media. They want the dialogue too. #lcsm |
| Dr Samer Al-Bothaigi @SalemSamer RT @BrendonStilesMD: T5. Scan the literature and ask questions. Reach out to authors, especially those on social media. They want the dialogue too. #lcsm |
| Dr Samer Al-Bothaigi @SalemSamer RT @BrendonStilesMD: T5. Several websites try to update news from the field and to put it in common language. https://t.co/0fkUOn6Xpz #lcsm |
| Laura Greco @lgreco_ny RT @KAdvocate_LCAM: YES! YES! YES! #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. Scan the literature and ask questions. Reach out to authors, especially those on social media. They want the dialogue too. #lcsm |
| Brendon Stiles @BrendonStilesMD T5. Don’t be afraid to ask researchers to describe their work in practical terms. If they can’t, it just might not be impactful! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. Several websites try to update news from the field and to put it in common language. https://t.co/0fkUOn6Xpz #lcsm |
| Anita Figueras @scifiknitter RT @BrendonStilesMD: T5. Several websites try to update news from the field and to put it in common language. https://t.co/0fkUOn6Xpz #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. @SurvivorNetTeam does a good job of keeping an eye on scientific advances and explaining them in lay terms. https://t.co/Hy924wM24j #lcsm |
| Kathleen Skambis @KathleenSkambis T5. Keep telling everyone you meet how interested you are in area and ask for their help. #lcsm |
| Brendon Stiles @BrendonStilesMD @VirginiaMByrne Lame. #lcsm |
| Kristin Ito @KAdvocate_LCAM @BrendonStilesMD @SurvivorNetTeam Thank you for sharing this! #LCSM |
| Geoff Hugo @gdhugo RT @BrendonStilesMD: T5. @SurvivorNetTeam does a good job of keeping an eye on scientific advances and explaining them in lay terms. https://t.co/Hy924wM24j #lcsm |
| #LCSM Chat @lcsmchat RT @VirginiaMByrne: #lcsm At MSKCC it's against the "rules" to email docs or nurses. I find that so backwards. |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. Don’t be afraid to ask researchers to describe their work in practical terms. If they can’t, it just might not be impactful! #lcsm |
 | Radio pedia MEXICO @RadioOncopediat RT @IanJPereira: T2 - more creative ways to fund more studies, including in radiation treatment for #LungCancer. #RTDrugCombo? #lcsm #RadOnc |
| #LCSM Chat @lcsmchat RT @KathleenSkambis: T5. Keep telling everyone you meet how interested you are in area and ask for their help. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T5. Don’t be afraid to ask researchers to describe their work in practical terms. If they can’t, it just might not be impactful! #lcsm |
| Aparna Hegde, MD @notahedge @cancerGRACE is also an excellent resource #lcsm |
| Brendon Stiles @BrendonStilesMD T5. Go to your local cancer hospital and ask what is happening in lung cancer research! Dialogue is key. #lcsm |
| Dr Samer Al-Bothaigi @SalemSamer RT @BrendonStilesMD: T5. Don’t be afraid to ask researchers to describe their work in practical terms. If they can’t, it just might not be impactful! #lcsm |
| Brendon Stiles @BrendonStilesMD T5. Joining local IRBs or other committees is also a great way to learn and make a difference. #lcsm |
| Ian Pereira @IanJPereira @lgreco_ny Not easy to advocate for oneself, let alone others, when sick. However, supportive, accessible communities (like #lcsm) can amplify voices beyond their physical boundaries. T3 |
| Brendon Stiles @BrendonStilesMD @notahedge @cancerGRACE Very true! #lcsm |
| #LCSM Chat @lcsmchat RT @notahedge: @cancerGRACE is also an excellent resource #lcsm |
| Christine Qiong Wu @wi_qiong @BrendonStilesMD T5, good to know.#lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. Go to your local cancer hospital and ask what is happening in lung cancer research! Dialogue is key. #lcsm |
| Brendon Stiles @BrendonStilesMD T5. Many lung cancer organizations have committees in which patients can be involved. Yes, do advocacy and education, but ask about research too! #lcsm |
| Jean Parks @geekbabe @BrendonStilesMD Every picture tells a cancer patient’s story #LCSM https://t.co/jS4T1ruZ6p |
| Flemming Rasmussen @fgrazz @BrendonStilesMD T5 - this in spades...one of the hardest things is getting the right narrative in a story that connects #lcsm |
| Dr Samer Al-Bothaigi @SalemSamer RT @IanJPereira: @lgreco_ny Not easy to advocate for oneself, let alone others, when sick. However, supportive, accessible communities (like #lcsm) can amplify voices beyond their physical boundaries. T3 |
| Paula @lungcancer1964 RT @BrendonStilesMD: T2. We need to understand why so many patients develop resistance to drugs that initially work. #lcsm https://t.co/hSuGu1OjYm |
| Brendon Stiles @BrendonStilesMD T5. I love it that @ALKLungCancer (ALKPositive), @EGFRResisters, @ROS1ders and others are asking for a stake in research. #lcsm |
| Ian Pereira @IanJPereira RT @BrendonStilesMD: T3. For scientific manuscripts, visual abstracts are awesome and easy to disseminate. #lcsm https://t.co/Z9Ld0yEKok |
| Brendon Stiles @BrendonStilesMD Love. #lcsm https://t.co/YianVJveVv |
| Paula @lungcancer1964 RT @BrendonStilesMD: T2. We need to figure out who is at risk for lung cancer, particularly among never smokers. Data from us @WeillCornell @MeyerCancer #lcsm https://t.co/mJBP6TbZ6F |
| Brendon Stiles @BrendonStilesMD Love. #lcsm https://t.co/a3qOfqa6RO |
| Jean Parks @geekbabe RT @IanJPereira: @lgreco_ny Not easy to advocate for oneself, let alone others, when sick. However, supportive, accessible communities (like #lcsm) can amplify voices beyond their physical boundaries. T3 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @geekbabe: @BrendonStilesMD Every picture tells a cancer patient’s story #LCSM https://t.co/jS4T1ruZ6p |
| Brendon Stiles @BrendonStilesMD Love. #lcsm https://t.co/SQyOjkVcBg |
| Laura Greco @lgreco_ny 75 Patients can get involved as reviewers for those programs that (rightly) value the patient perspective, such as @CDMRP . Then, when other organizations fail to have patients present (including lung orgs), ask, "Why not"? I guarantee you no one at the table cares more. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. Joining local IRBs or other committees is also a great way to learn and make a difference. #lcsm |
| #LCSM Chat @lcsmchat RT @IanJPereira: @lgreco_ny Not easy to advocate for oneself, let alone others, when sick. However, supportive, accessible communities (like #lcsm) can amplify voices beyond their physical boundaries. T3 |
| Brendon Stiles @BrendonStilesMD T5. Every grant funding panel I have ever been on that includes a patient or advocate has been BETTER because of it. #lcsm |
| Devika Das, MD, MSHQS @DevikaDasMD @BrendonStilesMD T5 Active input in clinical trial designs, larger inclusion in panels at national meetings, advocacy in Washington for more research funding, engage other patients and caregivers to do the same #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. Many lung cancer organizations have committees in which patients can be involved. Yes, do advocacy and education, but ask about research too! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. I love it that @ALKLungCancer (ALKPositive), @EGFRResisters, @ROS1ders and others are asking for a stake in research. #lcsm |
| Brendon Stiles @BrendonStilesMD RT @fgrazz: @BrendonStilesMD T5 - this in spades...one of the hardest things is getting the right narrative in a story that connects #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: T5. Every grant funding panel I have ever been on that includes a patient or advocate has been BETTER because of it. #lcsm |
| #LCSM Chat @lcsmchat RT @lgreco_ny: 75 Patients can get involved as reviewers for those programs that (rightly) value the patient perspective, such as @CDMRP . Then, when other organizations fail to have patients present (including lung orgs), ask, "Why not"? I guarantee you no one at the table cares more. #lcsm |
| Jean Parks @geekbabe RT @lgreco_ny: 75 Patients can get involved as reviewers for those programs that (rightly) value the patient perspective, such as @CDMRP . Then, when other organizations fail to have patients present (including lung orgs), ask, "Why not"? I guarantee you no one at the table cares more. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. Every grant funding panel I have ever been on that includes a patient or advocate has been BETTER because of it. #lcsm |
| #LCSM Chat @lcsmchat RT @DevikaDasMD: @BrendonStilesMD T5 Active input in clinical trial designs, larger inclusion in panels at national meetings, advocacy in Washington for more research funding, engage other patients and caregivers to do the same #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @lgreco_ny: 75 Patients can get involved as reviewers for those programs that (rightly) value the patient perspective, such as @CDMRP . Then, when other organizations fail to have patients present (including lung orgs), ask, "Why not"? I guarantee you no one at the table cares more. #lcsm |
| Dr Samer Al-Bothaigi @SalemSamer RT @BrendonStilesMD: Love. #lcsm https://t.co/SQyOjkVcBg |
| Brendon Stiles @BrendonStilesMD T5. @cdmrp does a great job involving patients/advocates as peer reviewers. https://t.co/t01HPrn4nd #lcsm https://t.co/r20E3WlIfG |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: Love. #lcsm https://t.co/SQyOjkVcBg |
| Brendon Stiles @BrendonStilesMD T5. And @AACR has an amazing Scientist-Survivor Program. https://t.co/9SRv5YSAZk #lcsm |
| Laura Greco @lgreco_ny @BrendonStilesMD @ALKLungCancer @EGFRResisters t5: New additional group, @alk_fusion It's really focusing in on the concept of patients as partners. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. @cdmrp does a great job involving patients/advocates as peer reviewers. https://t.co/t01HPrn4nd #lcsm https://t.co/r20E3WlIfG |
| Bob Steele @steele_bob RT @Tony_Calles: Chemotherapy looks better for low bTMB based on OAK/POPLAR trial in 2nd line NSCLC #ELCC19 #LCSM #OncoAlert https://t.co/Qgmj29v6qf |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @DevikaDasMD: @BrendonStilesMD T5 Active input in clinical trial designs, larger inclusion in panels at national meetings, advocacy in Washington for more research funding, engage other patients and caregivers to do the same #lcsm |
| Brendon Stiles @BrendonStilesMD Almost time to wind the chat down. This has been an incredible discussion. #lcsm |
| Ian Pereira @IanJPereira @KathleenSkambis Great point - perhaps these can be built into studies to make them more accessible (e.g. free parking slips, or #telemedicine) T3 #lcsm |
| Brendon Stiles @BrendonStilesMD Please share your closing thoughts! #lcsm |
| Aparna Hegde, MD @notahedge #lcsm look at these smarties presenting at #AACR19 |
 | Amir Safavi @safaviaa RT @BrendonStilesMD: T5. Every grant funding panel I have ever been on that includes a patient or advocate has been BETTER because of it. #lcsm |
| Dr Samer Al-Bothaigi @SalemSamer RT @BrendonStilesMD: Almost time to wind the chat down. This has been an incredible discussion. #lcsm |
| Laura Greco @lgreco_ny RT @BrendonStilesMD: T5. @cdmrp does a great job involving patients/advocates as peer reviewers. https://t.co/t01HPrn4nd #lcsm https://t.co/r20E3WlIfG |
| Flemming Rasmussen @fgrazz @BrendonStilesMD T5 - re funding panels. There are not many means to get ideas fm the outside looked at, except by private investors #lcsm |
| Devika Das, MD, MSHQS @DevikaDasMD RT @lgreco_ny: 75 Patients can get involved as reviewers for those programs that (rightly) value the patient perspective, such as @CDMRP . Then, when other organizations fail to have patients present (including lung orgs), ask, "Why not"? I guarantee you no one at the table cares more. #lcsm |
| Jean Parks @geekbabe We are husbands,wives, parents, grandparents, workers, friends.. not just cancer patients. We matter, our lives matter #LCSM |
| Kathleen Skambis @KathleenSkambis These chats are SO worthwhile. Thank you. #lcsm |
| Brendon Stiles @BrendonStilesMD #Research has to be doing something right. Whether it is research into causes and prevention, screening, or new therapeutics - we are making progress. #lcsm https://t.co/6aOAdkygsJ |
| Anita Figueras @scifiknitter RT @BrendonStilesMD: T5. I love it that @ALKLungCancer (ALKPositive), @EGFRResisters, @ROS1ders and others are asking for a stake in research. #lcsm |
| Laronica Conway @louisianagirl91 RT @BrendonStilesMD: T5. Every grant funding panel I have ever been on that includes a patient or advocate has been BETTER because of it. #lcsm |
| Flemming Rasmussen @fgrazz RT @KathleenSkambis: These chats are SO worthwhile. Thank you. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD This #lcsm |
| Paula @lungcancer1964 RT @BrendonStilesMD: T2. We also need to understand financial toxicity of cancer care today and how that impacts patients and caregivers. #lcsm https://t.co/1Rj1lAuMTj |
| Lung Cancer #1 cancer killer of women @VirginiaMByrne T5 They have the greatest stake in research! |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. And @AACR has an amazing Scientist-Survivor Program. https://t.co/9SRv5YSAZk #lcsm |
| Brendon Stiles @BrendonStilesMD Let's not let up. Keep #Research strong. #lcsm https://t.co/1J0Ht5JoaW |
| #LCSM Chat @lcsmchat RT @lgreco_ny: @BrendonStilesMD @ALKLungCancer @EGFRResisters t5: @BrendonStilesMD @ALKLungCancer @EGFRResisters t5: New additional group, @alk_fusion It's really focusing in on the concept of patients as partners. #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @BrendonStilesMD: #Research has to be doing something right. Whether it is research into causes and prevention, screening, or new therapeutics - we are making progress. #lcsm https://t.co/6aOAdkygsJ |
| Kristin Ito @KAdvocate_LCAM Thank you @BrendonStilesMD for hosting! To learn more about the STARS program, please visit: https://t.co/CQyycc5Z87 #LCSM #strongertogether |
| Bob Steele @steele_bob RT @BrendonStilesMD: Let's not let up. Keep #Research strong. #lcsm https://t.co/1J0Ht5JoaW |
| Lung Cancer #1 cancer killer of women @VirginiaMByrne #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Almost time to wind the chat down. This has been an incredible discussion. #lcsm |
| #LCSM Chat @lcsmchat RT @IanJPereira: @KathleenSkambis Great point - perhaps these can be built into studies to make them more accessible (e.g. free parking slips, or #telemedicine) T3 #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Please share your closing thoughts! #lcsm |
| Aparna Hegde, MD @notahedge #AACR19 had a survivor scientist program this year. Ask these organizations how to get involved #lcsm @ivybelkins @jillfeldman4 @EGFRResisters |
| #LCSM Chat @lcsmchat RT @notahedge: #lcsm look at these smarties presenting at #AACR19 |
| #LCSM Chat @lcsmchat RT @fgrazz: @BrendonStilesMD T5 - re funding panels. There are not many means to get ideas fm the outside looked at, except by private investors #lcsm |
| #LCSM Chat @lcsmchat RT @geekbabe: We are husbands,wives, parents, grandparents, workers, friends.. not just cancer patients. We matter, our lives matter #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: #Research has to be doing something right. Whether it is research into causes and prevention, screening, or new therapeutics - we are making progress. #lcsm https://t.co/6aOAdkygsJ |
| Dr Samer Al-Bothaigi @SalemSamer Thanks #some social media @twitter that allowed me to share this chat with Even though i am far away from USA See you soon Peace upon you From the land of war Yemen #lcsm |
 | Laura A. Fiorenza @LauraAFiorenza A truly educational, engaging presentation and discussion bringing the MD/NP/patient perspectives on EGFR+ lung cancer - thank you for sharing your stories. @EGFRResisters #ONSCongress #lcsm |
| Brendon Stiles @BrendonStilesMD Another way to think about it! #lcsm https://t.co/Raxa5FOAWO |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Let's not let up. Keep #Research strong. #lcsm https://t.co/1J0Ht5JoaW |
| #LCSM Chat @lcsmchat RT @KAdvocate_LCAM: Thank you @BrendonStilesMD for hosting! To learn more about the STARS program, please visit: Thank you @BrendonStilesMD for hosting! To learn more about the STARS program, please visit: https://t.co/CQyycc5Z87 #LCSM #strongertogether |
| Jean Parks @geekbabe I see so many more young people in the waiting room than ever before. Research is key to helping #LCSM |
| #LCSM Chat @lcsmchat RT @VirginiaMByrne: #lcsm |
| Denise Cutlip @dennycee RT @lgreco_ny: @BrendonStilesMD @ALKLungCancer @EGFRResisters t5: @BrendonStilesMD @ALKLungCancer @EGFRResisters t5: New additional group, @alk_fusion It's really focusing in on the concept of patients as partners. #lcsm |
 | Peggy Dennis @peggyddennis Sorry to join late. These chats are informative and helpful. Research Rocks! #lcsm |
| Anita Figueras @scifiknitter RT @lgreco_ny: 75 Patients can get involved as reviewers for those programs that (rightly) value the patient perspective, such as @CDMRP . Then, when other organizations fail to have patients present (including lung orgs), ask, "Why not"? I guarantee you no one at the table cares more. #lcsm |
 | Matthias Scheffler @trnsltnl RT @Tony_Calles: VARGADO: VARGADO: Nintedanib + Docetaxel in 3rd line after 2nd line Immunotherapy in NSCLC. Encouraging results from real clinical practice. #ELCC19 #LCSM #OncoAlert https://t.co/6zGkQjFFCT |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Yes, thank you, @BrendonStilesMD #lcsm |
| #LCSM Chat @lcsmchat RT @LauraAFiorenza: A truly educational, engaging presentation and discussion bringing the MD/NP/patient perspectives on EGFR+ lung cancer - thank you for sharing your stories. @EGFRResisters #ONSCongress #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Another way to think about it! #lcsm https://t.co/Raxa5FOAWO |
| Brendon Stiles @BrendonStilesMD #Research moves the needle. Without a doubt. #lcsm https://t.co/NXhOkYBW8g |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @BrendonStilesMD It also means publishing/sharing negative #research findings to avoid wasting precious funding on less worthwhile hypotheses #lcsm |
| Paula @lungcancer1964 RT @KAdvocate_LCAM: @BrendonStilesMD Create digestible summary slides whenever they present at conferences! #LCSM |
| Brendon Stiles @BrendonStilesMD Look how far we have come in lung cancer in a very short time. #lcsm https://t.co/4L7D0EhXmh |
| #LCSM Chat @lcsmchat Thank you @BrendonStilesMD for another excellent moderating stint! #LCSM |
| Bob Steele @steele_bob RT @BrendonStilesMD: Look how far we have come in lung cancer in a very short time. #lcsm https://t.co/4L7D0EhXmh |
| Matthias Scheffler @trnsltnl RT @BrendonStilesMD: T5. I love it that @ALKLungCancer (ALKPositive), @EGFRResisters, @ROS1ders and others are asking for a stake in research. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: #Research moves the needle. Without a doubt. #lcsm https://t.co/NXhOkYBW8g |
| #LCSM Chat @lcsmchat RT @subatomicdoc: @BrendonStilesMD It also means publishing/sharing negative #research findings to avoid wasting precious funding on less worthwhile hypotheses #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Look how far we have come in lung cancer in a very short time. #lcsm https://t.co/4L7D0EhXmh |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #Hope #lcsm |
| Dr Samer Al-Bothaigi @SalemSamer We can use social media to conduct multi-hospitals collaborative researches. From all over the world #lcsm |
| Jean Parks @geekbabe Thank you for the chat... I suspect finishing my taxes will get me before my cancer does #LCSM 😀 |
| Deb Smith 🌻 @debsmithbeach RT @BrendonStilesMD: Let's not let up. Keep #Research strong. #lcsm https://t.co/1J0Ht5JoaW |
| Dr Samer Al-Bothaigi @SalemSamer RT @BrendonStilesMD: Look how far we have come in lung cancer in a very short time. #lcsm https://t.co/4L7D0EhXmh |
| Brendon Stiles @BrendonStilesMD Found this great graphic. Good summary of why patients should engage in research. #lcsm https://t.co/zOSXehQmhk |
| Laura Greco @lgreco_ny RT @subatomicdoc: @BrendonStilesMD It also means publishing/sharing negative #research findings to avoid wasting precious funding on less worthwhile hypotheses #lcsm |
| Devika Das, MD, MSHQS @DevikaDasMD RT @BrendonStilesMD: Look how far we have come in lung cancer in a very short time. #lcsm https://t.co/4L7D0EhXmh |
| Brendon Stiles @BrendonStilesMD Thanks to all of the #lcsm community who joined. And BIG thanks to all of our guests tonight. Incredible turnout! #lcsm |
| Christine Qiong Wu @wi_qiong @lcsmchat @BrendonStilesMD Thank you for your encouagement. #lcsm |
 | Parneet Cheema @drcheema_cancer RT @CurrentOncology: Canadian consensus: Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer https://t.co/fhQkiXTIqq #nsclc #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @BrendonStilesMD: Look how far we have come in lung cancer in a very short time. #lcsm https://t.co/4L7D0EhXmh |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: Found this great graphic. Good summary of why patients should engage in research. #lcsm https://t.co/zOSXehQmhk |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Found this great graphic. Good summary of why patients should engage in research. #lcsm https://t.co/zOSXehQmhk |
 | KC Dill @kasedill I missed this informative chat tonight. Can’t wait to look over the notes time change got me. #lcsm |
| Aparna Hegde, MD @notahedge @BrendonStilesMD When I started fellowship there was only platinum doublet. The scene exploded over the past 4 years. #lcsm |
| Brendon Stiles @BrendonStilesMD Thanks to everyone for participating! #lcsm |
| Dr Samer Al-Bothaigi @SalemSamer RT @BrendonStilesMD: Found this great graphic. Good summary of why patients should engage in research. #lcsm https://t.co/zOSXehQmhk |
| Anita Figueras @scifiknitter RT @subatomicdoc: @BrendonStilesMD It also means publishing/sharing negative #research findings to avoid wasting precious funding on less worthwhile hypotheses #lcsm |
| Devika Das, MD, MSHQS @DevikaDasMD Closing thoughts - Screening saves lives. Need more robust lung cancer screening inplemtnation and continued research to study its impact #lcsm |
| Parneet Cheema @drcheema_cancer RT @PercyLeeMD: Practice changing paradigm. #sabr stereotactic ablative radiotherapy for oligometaststic disease state #lcsm #pcsm #bcsm #radonc |
| Paula @lungcancer1964 RT @lgreco_ny: t3 Fund scholarships so patients can go to medical conferences. Getting a scholarship can feel like winning the lotto because it is so rare. #lcsm |
| Dr Samer Al-Bothaigi @SalemSamer RT @BrendonStilesMD: Thanks to everyone for participating! #lcsm |
| Anita Figueras @scifiknitter RT @BrendonStilesMD: Look how far we have come in lung cancer in a very short time. #lcsm https://t.co/4L7D0EhXmh |
| Bob Steele @steele_bob This has been Par Excellence! Thanks all for the great info. Look forward to seeing you at next month's LUNG CANCER SOCIAL MEDIA Twitter Chat Session. Good night all. #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @notahedge: #AACR19 had a survivor scientist program this year. Ask these organizations how to get involved #lcsm @ivybelkins @jillfeldman4 @EGFRResisters |
| Aparna Hegde, MD @notahedge @BrendonStilesMD When I started fellowship there was only platinum doublet besides TKIs for NSCLC. Over 4 years, have had to learn and relearn constantly and I love it! #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @BrendonStilesMD: Please share your closing thoughts! #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @lgreco_ny: 75 Patients can get involved as reviewers for those programs that (rightly) value the patient perspective, such as @CDMRP . Then, when other organizations fail to have patients present (including lung orgs), ask, "Why not"? I guarantee you no one at the table cares more. #lcsm |
| Amir Safavi @safaviaa RT @BrendonStilesMD: Look how far we have come in lung cancer in a very short time. #lcsm https://t.co/4L7D0EhXmh |
| Amir Safavi @safaviaa RT @KathleenSkambis: T3. In addition to costs of treatment, trial costs of note to patients include simple things, like parking costs. #lcsm |
| Bob Steele @steele_bob RT @notahedge: @BrendonStilesMD When I started fellowship there was only platinum doublet besides TKIs for NSCLC. Over 4 years, have had to learn and relearn constantly and I love it! #lcsm |
| Brendon Stiles @BrendonStilesMD We have come a long way from this. But research got us there. And research will take us farther. #lcsm https://t.co/Zbh1RcoKiq |
| Laronica Conway @louisianagirl91 Thank you for providing some really important info for patients and their caregivers! Research isn’t just for “scientists”! We all deserve to know how we can benefit from research! #researchsaveslives #lcsm |
| Deb Smith 🌻 @debsmithbeach @BrendonStilesMD Thanks to you too! #LCSM |
 | Dr. David Tom Cooke @DavidCookeMD RT @BrendonStilesMD: Look how far we have come in lung cancer in a very short time. #lcsm https://t.co/4L7D0EhXmh |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: We have come a long way from this. But research got us there. And research will take us farther. #lcsm https://t.co/Zbh1RcoKiq |
 | Alex Tan @DrAlexTan RT @_ShankarSiva: It's here! SABR-COMET published in @TheLancet - https://t.co/lZmAYZ3xWK - randomised trial of ablation in oligometastastic (1-5) #cancer. Double median PFS (6 mo vs 12 mo) and increased med overall survival (28 mo vs 41mo, p=0.09). @drdavidpalma et al. #lcsm #pcsm #radonc #tssmn https://t.co/kkdnHTSqrB |
| Paula @lungcancer1964 RT @KAdvocate_LCAM: Thank you @BrendonStilesMD for hosting! To learn more about the STARS program, please visit: Thank you @BrendonStilesMD for hosting! To learn more about the STARS program, please visit: https://t.co/CQyycc5Z87 #LCSM #strongertogether |
 | Geraldine McGinty @DrGMcGinty RT @BrendonStilesMD: T3. What can researchers do to make their work more accessible to patients and advocates? #lcsm |
| Aparna Hegde, MD @notahedge Research is amazing when its meaningful, purposeful and collaborative. Let's keep it going! Thanks for hosting the chat @BrendonStilesMD @lcsmchat As always, happy to reconnect with everyone. #lcsm |
 | Giorgos Tsaousis @g_tsaousis RT @n8pennell: Yes it will be nice to have option of pembro for some pts with PDL1 >1% but for MOST of these NSCLC pts chemo+pembro is still the standard of care, hope that message gets out! #LCSM https://t.co/2StlDjWg4Z via @onclive |
| Brendon Stiles @BrendonStilesMD Signing off! Thanks everyone for joining. Support #Research. Do #Research. Participate in #Research. Lives depend upon it. #lcsm https://t.co/wvjfefmFPX |
| Devika Das, MD, MSHQS @DevikaDasMD RT @debsmithbeach: T1. I've been in 3 clinical trials so far and 2/3 have benifitted me significantly! Happy to help future patients, thrilled to have extended my life! I've been on Tagrisso for 5 1/2 yrs, first in a trial. #LCSM |
| Geraldine McGinty @DrGMcGinty RT @BrendonStilesMD: T2. We have to figure out how to diagnose, test, and treat lung cancer better in rural communities. #NoDisparities #lcsm https://t.co/d4xxuSHFk4 |
| Deb Smith 🌻 @debsmithbeach RT @BrendonStilesMD: Signing off! Thanks everyone for joining. Support #Research. Do #Research. Participate in #Research. Lives depend upon it. #lcsm https://t.co/wvjfefmFPX |
| Geraldine McGinty @DrGMcGinty @cjeverett @FriedbergEric @LLALO |
 | Dr. Salazar @DrSalazarMejia RT @APassaroMD: #ELCC19 #lcsm Dr Chu discussing MYSTIC trial based on clinical characteristics, a very interesting point of view! Age and ECOG PS sub-g analyses 👉🏻Can we yet consider age > 65 yrs as elderly? 👉🏻 based on this results of PS0 vs 1...how to consider PS2? @oncology_bg https://t.co/7lsbkxep4b |
 | Waël Hanna @wc_hanna RT @BrendonStilesMD: Look how far we have come in lung cancer in a very short time. #lcsm https://t.co/4L7D0EhXmh |
 | Dhoruba Khali (She/Her/They) @DhorubaKhali The latest After The Ribbon Daily! https://t.co/yLaOkUHqjW Thanks to @Nastyness61 @itsmorenamorena @pn8h4g7y1fo #hiv #lcsm |
| Christine Qiong Wu @wi_qiong @notahedge @BrendonStilesMD @lcsmchat Well said. #lcsm |
| Geraldine McGinty @DrGMcGinty RT @BrendonStilesMD: T3. Bring patients to your labs or to research days. #lcsm |
| Geraldine McGinty @DrGMcGinty Or to tumor board like @SamirPatel_MD does |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @BrendonStilesMD Thanks for moderating #LCSM chat! |
 | Diana Jaimes @DianaJa21318387 RT @FDAOncology: FDA expands pembrolizumab indication for first-line treatment of non-small cell lung cancer (TPS ≥1%). #NSCLC #lcsm https://t.co/dQoPzmkeIv |
| Matthias Scheffler @trnsltnl RT @n8pennell: Yes it will be nice to have option of pembro for some pts with PDL1 >1% but for MOST of these NSCLC pts chemo+pembro is still the standard of care, hope that message gets out! #LCSM https://t.co/2StlDjWg4Z via @onclive |
 | Henning Willers, MD (he/him/his) @HenningWillers RT @_ShankarSiva: It's here! SABR-COMET published in @TheLancet - https://t.co/lZmAYZ3xWK - randomised trial of ablation in oligometastastic (1-5) #cancer. Double median PFS (6 mo vs 12 mo) and increased med overall survival (28 mo vs 41mo, p=0.09). @drdavidpalma et al. #lcsm #pcsm #radonc #tssmn https://t.co/kkdnHTSqrB |
 | Michelle Hershman @MichelleHersh11 RT @ivybelkins: @cancerGRACE Targeted Therapies Forum is starting right now with this awesome faculty! If you’re not in Philly, please go to https://t.co/9smbDkZeKX to watch us live! @Jbauml @JackWestMD @CharuAggarwalMD #lcsm #lungcancer @EGFRResisters @Exon20Group @ALKLungCancer @ros1cancer https://t.co/sMJIxnooZx |
| Ian Pereira @IanJPereira @notahedge Group in Europe is working on the #paywalls for publicly-funded research (https://t.co/IF4WzGZC0S), and more #OpenAccess manuscripts are on PubMed, but still a ways to go. #lcsm T3 |
| Ian Pereira @IanJPereira @BrendonStilesMD Thanks Dr. Stiles for organizing, and everyone in #lcsm for the great chat. Cheers from Toronto. |
| Jean Parks @geekbabe RT @BrendonStilesMD: Signing off! Thanks everyone for joining. Support #Research. Do #Research. Participate in #Research. Lives depend upon it. #lcsm https://t.co/wvjfefmFPX |
 | SiKiii @egogem7 RT @PercyLeeMD: Practice changing paradigm. #sabr stereotactic ablative radiotherapy for oligometaststic disease state #lcsm #pcsm #bcsm #radonc |
 | Ray Manneh Kopp @raymanneh RT @_ShankarSiva: It's here! SABR-COMET published in @TheLancet - https://t.co/lZmAYZ3xWK - randomised trial of ablation in oligometastastic (1-5) #cancer. Double median PFS (6 mo vs 12 mo) and increased med overall survival (28 mo vs 41mo, p=0.09). @drdavidpalma et al. #lcsm #pcsm #radonc #tssmn https://t.co/kkdnHTSqrB |
| Jean Parks @geekbabe RT @BrendonStilesMD: Found this great graphic. Good summary of why patients should engage in research. #lcsm https://t.co/zOSXehQmhk |
| Matthias Scheffler @trnsltnl CTX combi still preferable if PD-L1 <50%, no doubt. But at least justification that Pembro mono doesn‘t harm in these patients!@StephenVLiu @TonyMok9 #LCSM #ELCC19 |
| Jean Parks @geekbabe @BrendonStilesMD When I failed platinum doublet I figured I’d be dead within the yr. Research has kept me alive. Thanks for hosting #LCSM |
#LCSM content from Twitter.